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V. SUMMARY 
 
Mononuclear phagocytes play a pivotal role in lung host defence to inhaled 
pathogens by activation of both innate and adaptive immunity. Resident alveolar 
macrophages (AMs) are the primary mononuclear phagocytic cells found in the 
lower respiratory tract that play a central role in regulating pulmonary immune 
responses. Circulating mononuclear phagocytes (MPs) recruited into inflamed 
lungs, however are increasingly implicated as essential players in defence against 
a range of inhaled pathogens.  
To further elucidate the function of mononuclear phagocytes in regulating 
pulmonary immune responses we analysed molecular programs induced by 
bacterial ligands that are recognized by different TLRs. First, we discovered that 
TLR2 ligand Pam3CSK4 and TLR4 ligand LPS induced in AMs the expression of 
PKR, previously identified as an essential component of the innate antiviral 
response. More important we found that both TLR2 and TLR4 agonists induced 
rapid phosphorylation of PKR strictly dependent on the functionality of the 
respective TLR. Pharmacologic inhibition of PKR activity using 2-aminopurine  
(2-AP) and PKR gene deletion were found to reduce the TLR2/4-induced activation 
of the JNK signalling pathway (MKK4/JNK/c-Jun), but did not affect p38 and 
ERK1/2 activation. Moreover, inhibition of PKR phosphorylation severely impaired 
TNF- and IL-6 production by AMs in response to LPS and Pam3CSK4. 
Additionally, we found that PKR phosphorylation plays a major role in LPS but not 
Pam3CSK4-induced activation of the p65 subunit of NF-B. Collectively, these 
results indicate that functional PKR is critically involved in inflammatory responses 
of primary AMs to gram-positive as well as gram-negative bacteria cell wall 
components.  
In addition, we investigated the induction of lung inflammation and the concomitant 
MP recruitment after alveolar deposition of the TLR2 ligand Pam3CSK4. By using 
cell sorting, mRNA pre-amplification and whole genome oligonucleotide microarray 
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techniques we found that alveolar trafficking of MPs was associated with profound 
changes of their gene expression profiles post recruitment (~2500 genes 
increased). In particular, alveolar recruited MPs showed strong up-regulation for 
genes encoding cytokines/chemokines, PRR associated molecules and genes 
involved in eicosanoid metabolism. Interestingly, gene expression profiling 
revealed that lung recruited MPs displayed simultaneous induction of both pro- and 
anti-inflammatory genes. However, we observed a dynamic change of the genetic 
program of MPs found in BALF at different time intervals post challenge. Strong 
early induction of a subset of pro-inflammatory mediators such as TNF-, CCL2 
and IL-6 was found to decrease during the later resolution phase whereas 
increased transcript levels of central anti-inflammatory and pro-resolution 
mediators including IL-1RN, IRAK-M, IL-10 and BAX persisted at the same levels. 
Collectively, our in vivo study identifies for the first time the global genetic program 
activated in MPs at different time points during TLR2 ligand-induced recruitment to 
the alveolar space and thus may help to better understand how alveolar recruited 
MPS may contribute to the development and termination of pneumonia caused by 
gram-positive bacteria. 
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VI. ZUSAMMENFASSUNG 
 
Mononukleäre Zellen spielen eine entscheidende Rolle bei der angeborenen und 
adaptiven Immunabwehr von inhalierten Pathogenen. Alveolarmakrophagen (AM) 
stehen dabei an vorderster Front und spielen eine zentrale Rolle bei der 
Regulation der pulmonalen Immunantwort. Darüber hinaus wird in der letzten Zeit 
zunehmend klar, dass auch Monozyten, die aus dem Gefäßbett in das entzündete 
Lungengewebe einwandern, eine wesentliche Rolle in der Wirtsabwehr pulmonaler 
Infektionen spielen.  
Um die Rolle der residenten und rekrutierten mononukleären Zellpopulationen im 
Rahmen der pulmonalen Immunabwehr genauer zu untersuchen, analysierten wir 
Signaltransduktions-Kaskaden, die durch Pathogen-assoziierte Gefahrensignale 
über verschiedene Toll-like Rezeptoren in diesen Zellen induziert werden. Hierbei 
zeigte sich, dass Pam3CSK4 über TLR2 und LPS über TLR4 in AMs die 
Expression des Enzyms PKR induziert, das bislang als wichtige Komponente der 
angeborenen antiviralen Immunität bekannt war. Außerdem führt die Aktivierung 
von TLR2/4 zu einer sehr schnellen Phosphorylierung von PKR, was die 
Aktivierung nachgeschalteter Signaltransduktions-Kaskaden entscheidend 
mitbestimmt. So reduzierte die Inhibierung der PKR durch 2-Aminopurin (2-AP) 
oder die Gendeletion des PKR-Gens die TLR2/4-induzierte Aktivierung des  
JNK-Signalweges (MKK4/JNK/c-Jun). Im Gegensatz dazu erfolgte keine Inhibition 
der p38 und ERK1/2 Aktivierung. Darüber hinaus führte eine Inhibition der  
PKR-Phosphorylierung zu einer starken Hemmung der TNF- und IL-6-Produktion 
der AMs nach LPS- und Pam3CSK4-Stimulation. Außerdem konnten wir zeigen, 
dass die PKR-Phosphorylierung eine bedeutende Rolle bei der Aktivierung der 
LPS-induzierten, nicht jedoch der Pam3CSK4-induzierten Aktivierung der p65 
Untereinheit von NF-B spielt. Zusammenfassend legen diese Ergebnisse die 
Vermutung nahe, dass PKR eine kritische Rolle bei der durch 
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Zellwandbestandteile gram-positiver und –negativer Bakterien induzierten 
inflammatorischen Antwort von Alveolarmakrophagen spielt. 
In einem zweiten Ansatz untersuchten wir Mechanismen der Induktion einer 
pulmonalen Entzündungs-Reaktion und der nachfolgenden Einwanderung von 
Blut-Monozyten nach alveolärer Deposition des TLR2-Liganden Pam3CSK4. Wir 
kombinierten Zellsorting, mRNA-Präamplifikation und Gesamtgenom-Microarray 
Technologien, um Veränderungen des globalen genetischen Programms von 
Monozyten bei Einwanderung in den Alveolarraum zu untersuchen. Hierbei fanden 
sich tief greifende Veränderungen der Genexpression in den mononukleären 
Phagozyten nach alveolärer Rekrutierung, wobei die Expression von ca. 2500 
Genen signifikant erhöht war. Im Einzelnen konnten wir eine Erhöhung der 
Expression von Genen der Cytokin-und Chemokin-Familien, Pattern-Recognition-
Rezeptoren sowie Eiconsanoid-metabolisierenden Enzyme nachweisen. Dabei 
wurde interessanter Weise sowohl die Transkription pro- als auch 
antiinflammatorischer Gene induziert. Allerdings zeigten mononukleäre 
Phagozyten, die zu verschiedenen Zeitpunkten nach Pam3CSK4-induzierter 
Rekrutierung analysiert wurden, deutliche Unterschiede in ihrem 
Genexpressionsprofil: mRNA Spiegel von pro-inflammatorischen Mediatoren wie 
TNF-, CCL2 und IL-6 waren zu frühen Zeitpunkten stark erhöht und sanken dann 
rasch ab, während die ebenfalls bereits früh erhöhte Genexpression von zentralen 
anti-inflammatorischen Mediatoren wie IL-1RN, IRAK-M, IL-10 und BAX auch zu 
späteren Zeitpunkten persistierte. Zusammenfassend erfassen diese 
Untersuchungen zum ersten Mal detailliert das globale genetische Programm 
aktivierter mononukleärer Phagozyten zu unterschiedlichen Zeitpunkten nach 
TLR2-Ligand-induzierter Rekrutierung in den Alveolar-Raum. Dies erlaubt einen 
Einblick in das Funktionsrepertoire von mononukleären Phagozyten, mit dem diese 
zur pulmonalen Entzündungsinduktion und –terminierung bei durch gram-positive 
Bakterien hervorgerufenen Pneumonien beitragen können. 
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1 INTRODUCTION 
1.1 INNATE IMMUNITY 
All multi-cellular eukaryotic organisms are constantly exposed to millions of 
potential pathogens daily through contact, ingestion and inhalation. To effectively 
detect, control and eliminate invading microbial pathogens, higher vertebrates 
have developed two interacting protective systems: the innate and adaptive 
immune systems. Innate immunity is an evolutionary conserved host defence 
armentarium that provides initial protection against invading micro-organisms. 
Remarkably, innate immunity has a higher level of specificity in its ability to 
distinguish distinct danger signals from different origin than was originally thought. 
It employs soluble factors and germline-encoded receptors called pattern 
recognition receptors (PRRs) to recognize specific components of microbes called 
pathogen-associated molecular patterns (PAMPs). PAMPs are evolutionary 
conserved structures that are essential for microbial physiology and survival. 
PAMPs include for instance viral double-stranded RNA (dsRNA), 
lipopolysaccharide (LPS) derived from gram-negative bacteria, un-methylated CpG 
di-nucleotides or lipoproteins of bacteria and fungi (1, 2). Recognition of PAMPs by 
PRRs activates different intracellular signalling pathways that result in the 
increased production of inflammatory mediators such as cytokines and 
chemokines, as well as recruitment of immune cells to inflamed tissues. Among 
PRRs, Toll-like receptors (TLRs) were highlighted as key recognition structures of 
the innate immune system.  
1.1.1 Recognition of microbial components by pattern 
recognition receptors  
The innate immune system utilizes a variety of PRRs that can be expressed on the 
cell surface, in intracellular compartments, or secreted into the bloodstream and 
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tissue fluids. The effectors functions of PRRs after ligand binding include 
opsonization, activation of complement and coagulation cascades, phagocytosis, 
activation of pro-inflammatory signalling pathways, and induction of apoptosis. 
Functionally PRRs can be divided into three classes: secreted, endocytic, and 
signalling. Mannan-binding lectin (MBL), C-reactive protein (CRP), and serum 
amyloid protein (SAP) are secreted pattern recognition molecules, whereas 
macrophage mannose receptor (MMR) and macrophage scavenger receptor 
(MSR) represent endocytic PRRs. The TLR family is the most investigated class of 
signalling PRRs and appears to have a major role in the induction of immune and 
inflammatory responses (3). 
1.1.2 Toll-like receptors 
Following the discovery of the role of Drosophila melanogaster Toll receptor in 
antifungal immunity, a mammalian homologue of Toll protein termed Toll-like 
receptor (later named TLR4) was identified (4). The TLR family now consists of 13 
mammalian members: 10 human (TLR1–10) and 12 murine (TLR1–9 and  
TLR11–13) receptors, of which some are homologues (Table 1.1) (5). Structurally, 
the intracellular domain of TLRs shows similarity to that of the interleukin-1 
receptor (IL-1R) family and therefore is termed a Toll/IL-1R domain (TIR). The 
extracellular portion of TLR, however, is characterized by the presence of  
leucine-rich repeat (LRR) motifs, whereas the IL-1R family possesses extracellular 
immunoglobulin-like domains. LRR domains are implicated in the recognition of 
PAMPs (5, 6). The main PAMP ligands for TLR1 to TLR13 are summarised in 
table 1.1.  
TLR family members are expressed on various immune cells including monocytes, 
macrophages, dendritic cells (DCs), B cells, and even on non-myeloid cells such 
as epithelial cells and fibroblasts (7). While some TLRs have been found to be 
expressed primarily on the cell surface (TLR1, TLR2, TLR4, TLR5, TLR6 and 
TLR11) others are found almost completely in intracellular compartments such as 
endosomes (TLR3, TLR7, TLR8 and TLR9) (7). The cellular expression of TLRs is 
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modulated rapidly in response to various stimuli such as pathogens, cytokines and 
environmental stresses (7, 8). Of the TLRs identified so far, TLR4 and TLR2 have 
been the most extensively studied. 
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Table 1.1 Toll like receptors and their ligands 
N.D., not determined; TLR, Toll-like receptor. Modified and adapted from Akira 2004 and Takeda 
2003 (7-9). 
TLR1 Triacyllipopeptides Bacteria and Mycobacteria Human, mouse
Pam3CSK4 Synthetic compound
TLR2 Lipoteichoic acid Gram-positive bacteria Human, mouse
Peptidoglycan Gram-positive bacteria
Zymosan Fungi
Lipoproteins and lipopeptides Various pathogens
Heat-shock protein 70 Host
Porins Neisseria
Pam3CSK4 Synthetic compound
Atypical lipopolysaccharide Leptospira interrogans
Lipoarabinomannam Mycobacteria
TLR3 Double-stranded RNA Viruses Human, mouse
TLR4 Lipopolysaccharide Gram-negative bacteria Human, mouse
Fusion protein Respiratory syncytial virus 
Taxol Plants
Heat-shock protein 60/70 Host
Hylauronic acid fragments Host
Fibrinogen Host
TLR5 Flagellin Bacteria Human, mouse
TLR6 Diacyl lipopeptides Mycoplasma Human, mouse
Zymosan Fungi
Lipoteichoic acid Gram-positive bacteria
TLR7 Single-stranded RNA Viruses Human, mouse
Imiquimod Synthetic compound
Loxoribine Synthetic compound
Bropirimine Synthetic compound
TLR8 Single-stranded RNA Viruses Human, mouse
Imiquimod Synthetic compound
TLR9 Unmethylated CpG DNA Bacteria, viruses, yeast Human, mouse
Chromatin-IgG complexes Host
Hemozoin Protozoa
TLR10 N.D. N.D. Human
TLR11 N.D. Uropathogenic bacteria Mouse
Profilin-like molecule Toxoplasma gondii
TLR12, TLR13 N.D. Mouse
TLR Ligand Origin of ligand Animal Species
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1.1.2.1 Toll-like receptor 4 (TLR4) 
TLR4 is an essential receptor for the recognition of LPS (also referred as 
endotoxin), a major component of the outer membrane of gram-negative bacteria 
such as Escherichia coli or Salmonella typhimurium. The link between TLR4 and 
LPS appeared in studies showing that genetic mutation responsible for  
hypo-responsiveness to LPS in two naturally occurring mouse strains, C3H/HeJ 
and C7BL10/ScCr was within the TLR4 gene (10, 11). Similarly, mice with targeted 
deletion in the TLR4 gene are hypo-responsive to LPS (12). Later studies 
discovered that TLR4 is necessary for the signalling of a range of other pathogen 
components and also several endogenous host ligands (Table 1.1) (8).  
TLR4 is important for host defence against different types of microbes including 
Salmonella, Mycobacterium tuberculosis, Candida albicans or Haemophilus 
influenzae (13). However, TLR4 is not the sole receptor involved in LPS 
recognition. LPS first interacts with a plasma protein named LPS-binding protein 
(LBP) to form stable LBP:LPS complexes that are recognized by the CD14 
receptor on the cell surface (14). CD14 is a membrane glycoprotein anchored in 
the lipid bilayer by its glycosylinositol (GPI) tail and is preferentially expressed on 
monocyte/macrophage and neutrophil (8). CD14 can also circulate in soluble form 
in the plasma (15). The major role of CD14 is to concentrate LPS for effective 
binding to the constitutively associated TLR4/MD2 complex (16).  
1.1.2.2 Toll-like receptor 2 (TLR2) 
TLR2 is involved in the recognition of a variety of microbial and synthetic patterns 
including bacterial lipoproteins derived from gram-negative as well as gram-
positive bacteria (e.g., Staphylococcus aureus and Streptococcus pneumoniae) or 
mycoplasma spp. (Table 1.1) (8). TLR2 has also been reported to recognize 
several atypical forms of LPS such as LPS derived from Leptospira interrogans 
(17). 
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The wide spectrum of ligand recognition by TLR2 is mostly determined by 
heterodimeric interaction with other TLR family members such as TLR1 or TLR6. 
For example, TLR2/TLR1 complex recognizes synthetic triacylated lipoproteins 
such as Pam3CSK4, whereas TLR2/TLR6 complexes recognize diacylated 
lipoproteins including mycoplasmal macrophage-activating lipopeptide 2 (MALP-2) 
(8, 18). In addition, TLR2 has been shown to cooperate with distinct types of other 
receptors such as dectin-1 to recognize fungal -glucans, as well as with CD36 to 
recognize diacylglycerides (19). TLR2-deficient mice were found to be highly 
susceptible to challenge with S. aureus and S. pneumoniae (13, 20). 
1.1.3 TLR-mediated signalling pathways 
Binding of microbial components to their respective TLR triggers activation of 
signalling pathways, which all make use of adapter proteins (Figure 1.1). Four TIR 
domain containing adaptors, namely myeloid differentiation primary-response gene 
88 (MyD88), TolI/interleukin-1 receptor domain-containing adapter protein 
(TIRAP/Mal), TIR-containing adaptor protein inducing interferon (IFN)- 
(TRIF/TICAM1) and TRIF-related adaptor molecule (TRAM/TICAM-2) were shown 
to play important roles in the TLR signalling pathway. MyD88 is essential for the 
induction of inflammatory responses triggered by all TLRs with the exception of 
TLR3 (7). TIRAP is specifically involved in the MyD88-dependent pathway via 
TLR2 and TLR4, whereas TRIF is implicated in the TLR3- and TLR4-mediated 
MyD88-independent pathways (2, 21).  
The MyD88-dependent pathway includes a number of signalling molecules such 
as serine/threonine kinase IL-1R-associated kinase (IRAK), tumour necrosis factor 
(TNF)- receptor-associated factor 6 (TRAF6), transforming growth factor (TGF)--
activated kinase 1 (TAK1) and TAK1 binding protein-1 (TAB1). Generally, upon 
stimulation with PAMPs, MyD88 recruits IRAK4 to ligated TLRs to facilitate IRAK4 
mediated phosphorylation of IRAK1 and IRAK2. Activated IRAK1 associates with 
TRAF6 and together with TAK1 leads to the activation of two distinct pathways: the 
mitogen-activated protein kinases (MAPKs) and the Rel-family transcription factor 
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nuclear factor-B (NF-B). In consequence, the MyD88-dependent pathway leads 
to the production of inflammatory cytokines such as TNF-, IL-6, IL-12, and IL-1 
(5). However, subsequent studies have demonstrated that MyD88-independent 
activation of NF-B or interferon regulatory factor (IRF)-3 transcription factors 
occurs in TLR downstream signalling as well. This pathway has been implicated in 
the expression of IFN-inducible genes and LPS-mediated maturation of DCs (5).  
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Figure 1.1 Mammalian TLR signalling 
MyD88 is a Toll-like receptor (TLR) signalling adaptor protein that is used by all TLRs apart from 
TLR3. It interacts with the IRAK (interleukin-1 (IL-1) receptor-associated kinase) family, leading to 
interaction with TRAF6 (tumour-necrosis factor-receptor-associated factor 6), which ultimately leads 
to activation of nuclear factor-B (NF-B) and mitogen-activated protein (MAP) kinases such as 
p42/p44 MAP kinase and Jun N-terminal kinase (JNK). These pathways lead to the production of 
cytokines such as tumour-necrosis factor (TNF) and other pro-inflammatory proteins. MyD88 has 
recently been shown to have an additional role in the activation of IRF7 (interferon (IFN)-regulatory 
factor 7), which leads to induction of interferon-. TLR2 and TLR4 signalling specifically recruits a 
second adaptor, MAL, which is supposed to act mainly as a bridging adaptor for MyD88 
recruitment. TLR3 signals through TRIF (Toll/IL-1 receptor-domain containing adaptor protein 
inducing IFN-), which can specifically interact with the kinase TBK1 (TRAF-family-member-
associated NF-B activator-binding kinase 2) leading to IRF3 activation. Target genes for this 
pathway include IFN-. TRIF also interacts with RIP1 (receptor-interacting protein 1), which leads to 
activation of the IB (inhibitor of NF-B) kinase 1 (IKK1)–IKK2– NEMO complex. Finally, TRAM 
seems to be a bridging adaptor for TRIF recruitment, specifically for TLR4. UEV1A and UBC13 are 
ubiquitin-conjugating enzymes. 
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AP1, activator protein 1; BTK, Bruton’s tyrosine kinase; ECSIT, evolutionarily conserved signalling 
intermediate in Toll pathway; ISRE, IFN-stimulated response element; MKK, MAP kinase kinase; 
TAB2, transforming growth factor-activated kinase (TAK)-binding protein-2. Adapted from Liew 
2005 (22). 
 
1.1.3.1 Mitogen activated protein kinases in innate immune responses 
The MAP kinases are highly conserved signal transducing enzymes that are 
crucial for cell growth, differentiation and stress responses (23). At least three 
distinct MAPKs families have been described in mammalian cells: the extracellular 
signal-regulated protein kinase (ERK), c-Jun NH2-terminal kinase (JNK) and p38 
MAPK (24). MAP kinases signal through a three component protein kinase 
cascade: MAPK, MAPK kinase (MAPKK; MKK), and a MAPKK kinase (MAPKKK) 
(Figure 1.2) (23).  
 
 
 
Figure 1.2 Mammalian MAP kinase pathway 
Activation of MAP kinases by different stimuli first requires activation of specific MAPKK kinases 
(not shown) that in turn phosphorylate and activate specific MAPK kinases (MAPKK; MKK). MKK 
have a restricted specificity for MAP kinase substrates. MEK1 and MEK2 activate ERK MAP 
kinases; MKK3, MKK4 and MKK6 activate p38 MAP kinases; MKK4 and MKK7 activate the JNK 
pathway. Adapted and modified from Dong 2002 (24). 
 
9 
 
INTRODUCTION 
 
 
The classic ERK kinases include ERK1 and ERK2 which are often referred as 
p44/p42 MAP kinases. Upon activation, ERK1/2 translocate into the nucleus and 
phosphorylate numerous targets including transcription factors such as Elk-1. 
Many studies have demonstrated the importance of the ERK pathway in LPS 
signalling in monocytes and macrophages (25-27). Macrophages from  
Tpl2-deficient mice exhibited selective ERK deficits and reduced TNF- production 
upon LPS stimulation (28). Moreover, transport of TNF- mRNA from the nucleus 
to the cytoplasm was inhibited by specific ERK inhibitors (29). Inhibition of the 
MEK-ERK pathway in monocytes by U0126 reduced LPS induction of several 
inflammatory mediators including IL-1, IL-8, TNF- and prostaglandin (PG) E2 
(30). Similarly, blocking of the ERK pathway by PD98059 inhibited LPS induction 
of tissue factor gene expression in human monocytes (27). 
The JNK protein kinases, also known as stress-activated MAP kinases (SAPKs), 
are encoded by three genes: Jnk1, Jnk2 and Jnk3 (31). JNK kinases are activated 
through phosphorylation by MKK4 and MKK7 (31). JNK activation can be strongly 
induced in multiple cell types by LPS or inflammatory cytokines such as TNF- and 
IL-1 (24, 31). For instance, LPS stimulation of THP-1 and RAW 264.7 cells rapidly 
activates the JNK pathway (32). A critical role for JNK appears to be the regulation 
of the activator protein (AP)-1 transcription factor through phosphorylation of the N-
terminal part of c-Jun, a central component of AP-1 (29, 31). Inhibition of JNK 
activity results in decreased levels of TNF- in LPS-exposed macrophages (29). 
MKP5 is a negative regulator of JNK activity (33). Consequently, MKP5-deficient 
macrophages produced increased levels of inflammatory cytokines upon TLR 
ligand stimulation (34). 
The p38 MAPK (known as p38 ) was originally described as a 38-kDa polypeptide 
that was rapidly tyrosine phosphorylated in response to LPS and osmotic shock 
(35). Subsequently, three additional isoforms of p38 have been identified: ,  and 
. The p38 molecules are strongly activated by environmental stresses, 
inflammatory cytokines and bacterial ligands. Once activated, p38 MAPKs 
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modulate responses of different target proteins including transcription factors such 
as activating transcription factor (ATF)-2, signal transducer and activator of 
transcription (STAT)-1 and Elk-1. Lu and co-workers found that disruption of the 
MKK3-p38 MAP kinase pathway results in a selective defect in LPS-induced IL-12 
production, whereas the production of other cytokines such as TNF-, IL-6 and IL-
1 was comparable between wild type (WT) and knock-out (KO) mice (36). In 
another study, defects in the MK2 gene which is a common p38 substrate resulted 
in reduced serum levels of TNF-. Moreover, MK2-deficient mice displayed 
increased stress resistance and survival of endotoxin shock (37). 
1.1.3.2 Transcription factors involved in TLR-mediated signalling pathways 
Transcription factors tightly regulate the expression of inflammatory mediators. 
Stimulation with bacterial components induces activation of various transcription 
factors such as the NF-B, AP-1, STAT-1 and IRF family of transcription factors 
(38-40). 
NF-B represents a master transcription factor required for maximal expression of 
many genes including cytokines, growth factors, adhesion molecules and acute 
phase proteins (41). NF-B belongs to the Rel family of proteins that includes p50, 
p105, p52, p65, Rel B and c-Rel, which function as homo- and heterodimers (42, 
43). Under physiological conditions NF-B dimers are kept in the cytoplasm in an 
inactive state by inhibitors of B (IB). Upon stimulation, IB proteins are 
phosphorylated by IB kinases (IKKs) and NF-B proteins are released and 
translocated to the nucleus where they can bind to the specific gene regions (44). 
The most ubiquitous activated form of NF-B involved in LPS signalling is a 
heterodimer consisting of p50 and p65 subunits (29). Generally, regulation of NF-
B activity can be divided into four steps: nuclear translocation, phosphorylation, 
interaction with the basal transcription complex and redox regulation (45).  
The involvement of NF-B in the innate immune response has been studied 
broadly. Muller et al. have demonstrated for the first time that LPS can activate  
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NF-B in monocytic cells (46). In later studies NF-B activation has been linked to 
the production of TNF-, IL-1, IL-6, cyclooxygenase (COX)-2 and CC chemokine 
ligand 2 (CCL2, also referred to as monocyte chemoattractant protein (MCP)-1) in 
response to LPS (41). Studies using KO mice have shown that each member of 
the family plays an important role in LPS signalling. For instance, B cells from mice 
deficient in p50, p65, c-Rel, or Rel B displayed an impaired LPS response (43). In 
addition, mice deficient in functional subunits of NF-B were very susceptible to 
microbial infections (47-49).  
AP-1 represents another important family of transcription factors involved in TLR 
downstream signalling (29). This family is composed of homo- and heterodimers of 
the c-Jun and c-Fos family (50, 51). Activity of AP-1 is regulated through 
phosphorylation by JNK and ERK MAP kinases (52). Stimuli such as LPS, 
peptidoglycan and dsRNA enhance the transcriptional activity of AP-1 (29).  
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1.2 INNATE IMMUNITY IN THE LUNGS 
The lungs serve as a major interface between the host and the external 
environment. Each day, a human being breathes in and out more than 7000 L of 
air (29). Consequently, the respiratory tract is continuously exposed to numerous 
microbes, toxic gases and particles which are potentially harmful to the 
mammalian organism. Therefore, complex defence mechanisms of the respiratory 
tract from nostrils down to alveoli have been developed to protect the lung. The 
innate immune system of the lung consists of several physical, humoral and 
cellular components that work in concert in order to clear invading pathogens, 
preserve gas exchange, regulate inflammation and alert the adaptive immune 
system (Table 1.2).  
 
Table 1.2 Components of the innate immune system of the lung 
Adapted and modified from Beutler 2004 and Martin 2005 (53, 54). 
Physical component
nasopharyngeal anatomic barriers, cough, mucociliary apparatus
Humoral component
cytokines, chemokines, antimicrobial peptides, lipases, lactoferrins,  
lyzozyme,mannose-binding lectin, defensins, complement, 
acute phase proteins, immunoglobulins
Cellular component
alveolar macrophages, lung epithelial cells, monocytes, 
polymorphonuclear leukocytes, dendritic cells
 
 
Mechanisms such as coughing, sneezing and the mucociliary system in most 
cases effectively remove larger particulates from the upper airways. However, 
smaller particles, bacteria and viruses can escape the defence line of the upper 
airways and reach the alveolar space where they interact with soluble factors, 
pulmonary epithelium and mononuclear phagocytes (MPs). 
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1.2.1 Mononuclear phagocytes in lung host defence 
The MP system consists of bone marrow (BM) progenitor cells, monocytes, DCs 
and tissue macrophages. The major MPs subsets in airways and lung parenchyma 
are alveolar macrophages (AMs), with a CD11c+ CD11b- CX3CR1- surface 
phenotype, and CD11c+ CD11b+ CX3CR1+ lung DCs. (55, 56). Because of their 
phagocytic activity, antigen presentation capacity and secretion of soluble 
mediators MPs play a crucial role in lung innate and adaptive immune responses 
to pathogens.  
1.2.1.1 Resident alveolar macrophages 
AMs are specialized mononuclear phagocytic cells that function as a first host 
defence line against inhaled particles and pathogens in the lower respiratory tract 
(57). These cells are broadly distributed at the air-tissue interface in the alveolar 
space in close proximity to alveolar epithelial cells (AECs) and are separated by a 
distance of only 0.2–0.5 μm from interstitial DCs (58). AMs originate primarily from 
BM derived blood monocytes or may undergo limited local proliferation (59). 
Normally, AMs account for approximately 95% of airspace leukocytes of human 
lungs and 100% of the pathogen-free mice (54).  
AMs have ability to ingest all types of inhaled particulates that reach the alveolar 
space. Remarkably, AMs are generally poor initiators of lung immune responses, 
thereby keeping the airspace quiet and preserving the ability of the lung to perform 
gas exchange. They can remove and digest relatively inert particulates without 
triggering inflammatory responses that may damage the structural integrity of 
alveolar tissue (54, 58, 60). However, when pathogen exposures are sufficiently 
large or when faced with highly virulent pathogens, AMs initiate a localized 
inflammatory response by secretion of a wide array of mediators. These include 
cytokines (e.g. TNF- and IL-6), chemokines (e.g. CCL2 and RANTES) and lipid 
mediators (arachidonic metabolites) thereby promoting neutrophil, activated 
monocyte and lymphocyte sequestration at sites of inflammation in the lungs 
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(Table 1.3). To avoid uncontrolled AM activation, several regulatory mechanisms 
have been evolved. One possible inhibitory mechanism involves surfactant 
proteins A and D, which bind AM receptors and suppress inflammatory activity in 
uninfected lungs. Recently, Snelgrove et al. demonstrated a new mechanism by 
which AECs suppress AM activity under baseline conditions involving the negative 
regulator CD200 receptor (CD200R) on macrophages and its ligand CD200 on 
airway epithelium (60, 61). 
The ability of AMs to interact with microbes is mediated by surface receptors 
capable to bind specific ligands. The major receptors found on AMs include 
scavenger receptors, Fc receptors, G protein-coupled receptors (GPCRs), 
cytokines and chemokines receptors and TLRs (29). Among TLRs, function of 
TLR2 and TLR4 has been the most extensively studied. Both TLR2 and TLR4 
receptors are expressed and functionally active on AMs (62, 63). In AMs, 
recognition of LPS by TLR4 results in rapid activation of signalling pathways 
including all three major MAP kinases, p38, ERK1/2 and JNK in vitro and in vivo 
(29, 64). Likewise, activation of NF-B is an early event after LPS binding (as early 
as 30 min). It has been demonstrated that depletion of AMs attenuated NF-B 
activation in whole lung tissues and decreased the pro-inflammatory content in 
BALF. In addition to the initiation and regulation of inflammation, AMs actively 
participate in the resolution of inflammatory infiltrates and tissue repair by 
phagocytosis of apoptotic cells and elaboration of enzymes, anti-inflammatory 
cytokines (e.g. IL-1RN and IL-10) and growth factors such TGF-1 (Table 1.3).  
AMs have an additional role in the regulation of acquired immune responses. They 
can effectively suppress adaptive immunity by down-regulation of T- and B-cell 
activation and antigen presentation activities of DCs (65, 66). It has been 
demonstrated that in vivo depletion of AMs using clodronate-filled liposomes leads 
to significant increase in the pulmonary inflammatory response to harmless 
particulate and soluble antigens (67). 
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Table 1.3 Secretory products of alveolar macrophages 
IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; MCP, monocyte chemoattractant protein; 
RANTES, regulated upon activation normal T cell; MIP, macrophage inflammatory protein; GM-
CSF, granulocyte macrophage colony stimulating factor; G-CSF, granulocyte macrophage colony 
stimulating factor; M-CSF, macrophage colony stimulating factor; TGF, transforming growth factor; 
PDGF, platelet-derived growth factor; LTB, leukotriene B4; HETE, monohydroxyeicosatetraenoic 
acid; TIMP, tissue inhibitor of metalloproteinases. Adapted and modified from Nikod 1999 (68).  
Cytokines
IL-/, IL-1RN, TNF-, IFN-, IL-6, IL-10, IL-12, IL-23
Chemokines
IL-8, RANTES, MCP1/5, MIP-1/
Growth factors
GM-CSF, G-CSF, M-CSF, TGF-, PDGF
Lipid mediators
LTB4, 5-HETE
Reactive gases
Nitric oxide, Superoxide radical
Defensins and lizozyme
Complement
C3b, C5, C1q
Enzymes
Metalloelastases, Collagenase, TIMPs
Metalloproteases, Arginase I
 
 
1.2.1.2 Peripheral blood and alveolar recruited monocytes 
Peripheral blood (PB) monocytes are a heterogeneous cell population of 
circulating MPs that represent about 5–10% of PB leukocytes in humans and mice. 
Under steady-state condition, half of the circulating monocytes leave the 
bloodstream each day and following recruitment to the peripheral organs, they can 
differentiate into tissue macrophages or DCs. Bacterial infections or stimulation 
with PAMPs, however, heavily increase trafficking of monocytes to the site of 
inflammation, where they can contribute directly to immune defences against 
microbial pathogens and/or differentiate into resident MP (55, 59). 
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Figure 1.3 Monocyte differentiation into DCs and tissue macrophages  
Macrophage-DC progenitors (MDPs) give rise to Ly6C+ bone marrow monocytes, which exit the 
bone marrow, in part guided by CCR2-dependent signals. Ly6C+ monocytes convert into CX3CR1+ 
monocytes, although the location of this event, in the circulation or bone marrow, remains 
incompletely understood. Black arrows indicate differentiation steps into tissue DCs and 
macrophages that occur under homeostatic conditions. Red arrows indicate differentiation steps 
that occur under inflammatory conditions (UV-induced skin injury, intratracheal LPS administration, 
or depletion of autologous CD11c+ cells). Dashed arrows represent steps that remain uncertain. In 
the case of splenic cDCs, splenic pre-DCs are the most significant upstream precursor in numeric 
terms (bold arrow), although MDPs and CX3CR1+ monocytes may contribute as well. Adapted from 
Serbina 2007 (55). 
 
Mouse blood monocytes are identified primarily by their expression of receptor for 
monocyte colony stimulating factor (CSFR1, also referred to as CD115), CD11b 
and low levels of F4/80. They are derived from haematopoietic stem cell 
precursors that initiate myeloid differentiation and give rise to multipotent 
precursors (Lin-, Sca1+ and CD117+ positive cells). Recently myeloid lineage 
macrophage-DC progenitors (MDPs) have been isolated from BM of 
CX3CR1GFP knock-in mice. When introduced into BM, MDPs gave rise to Ly6C+ 
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and CXCR1+ BM monocytes from which subsequently the two principal circulating 
subsets are derived (Figure 1.3). One population (referred to herein as Ly6C+) 
expresses low levels of CX3CR1 (CX3CR1low), high levels of Ly6C (Ly6Chigh) and 
high levels of CCR2 (CCR2high). It has been demonstrated that Ly6C+ monocytes 
home to peripheral tissues in response to inflammatory stimuli, prompting their 
designation as inflammatory monocytes. This population corresponds to the main 
human monocyte population, which is CD14+ CD16- (so called CD14+). The 
second subset of mouse monocytes is similar to human CD14+ CD16+ monocytes 
and is defined by high levels of CX3CR1 (CX3CR1high), low levels of Ly6C 
(Ly6Clow) and CCR2 (CCR2low) (referred to herein as CX3CR1+). In contrast to 
Ly6C+, CX3CR1+ monocytes traffic into peripheral tissues under  
non-inflammatory conditions and therefore are referred to as non-inflammatory 
monocytes (55, 59). A more detailed description of the surface antigen expression 
on human and mouse monocyte subsets is summarized in the table 1.4. 
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Table 1.4 Surface antigen expression on murine and human monocyte subsets 
Adapted and modified from Serbina 2007 (55). 
 
 
Surface expression levels have been arbitrarily designated as undetectable (), marginal (+/), 
positive (+), and high (++) based on flow cytometric analysis; ND, not determined. 
b
 MHC class II levels are marginal under homeostatic conditions but increase rapidly with infectious 
or inflammatory stimulation. 
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Regardless of the pulmonary MPs, adoptively transferred CX3CR1+ monocytes 
traffic to the lungs of recipient mice, and these cells, along with Ly6C+ monocytes, 
give rise to pulmonary DCs. Innate immune activation, by infection or tissue injury, 
however results in increased recruitment of monocytes to inflamed tissues and 
under this conditions only CX3CR1+ monocytes give rise to lung macrophages and 
alveolar DCs as well (Figure 1.3) (55, 56). Subsequently macrophages and DCs 
regulate inflammatory response through elaboration of cytokines/chemokines, 
phagocytosis or antigen presentation. It is also known that before differentiation, 
recruited inflammatory monocytes may modulate local host defence responses. 
Besides their increased cytokine production and phagocytosis, monocytes are also 
able to kill bacteria by producing reactive nitrogen intermediates (RNIs) and 
reactive oxygen intermediates (ROIs) and through the action of phagolysosomal 
enzymes (55). Recently, MPs recruited to the alveolar space under acute 
inflammatory conditions were found to display a prominent  
pro-inflammatory phenotype manifested by increased levels of mRNA for TNF-, 
macrophage inflammatory protein (MIP)-2, KC, IFN-inducible protein (IP)-10 and 
various lysosomal proteases (69). Therefore freshly recruited inflammatory MPs 
may promote acute lung injury (ALI). Consequently monocytes were found to 
regulate neutrophilic influx during ALI (70). In addition, monocytes actively 
contribute to the both acute and chronic inflammatory disease such as acute 
respiratory distress syndrome (ARDS), bronchiolitis obliterans and idiopathic 
pneumonia syndrome (70-72). 
1.2.2 Lung inflammatory response 
The lung inflammatory response to microbial challenge is a complex process 
involving coordinated interaction of many inflammatory mediators, primarily 
cytokines and chemokines, various cell adhesion molecules (including P and E 
selectins) and different cell populations (including macrophages, epithelial cells 
and neutrophils) (73, 74). 
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Figure 1.4 Lung inflammatory response to microbial challenge  
TLR, Toll-like receptor; TNF, tumor necrosis factor; IL, interleukin; IFN, interferon; Th, T helper. 
Adapted from Strieter (74). 
 
Lung inflammatory response can be induced by alveolar deposition of bacterial 
components such as LPS. In the initial stages of inflammation bacterial ligands 
activate resident cells in lung interstitium and alveolus, primarily macrophages, to 
secrete pro-inflammatory cytokines such as TNF- and IL-1 and chemokines 
including RANTES, MIP-2 and KC (45, 54, 73) (Figure 1.4). These mediators act in 
concert to promote polymorphonuclear leukocyte (PMN) accumulation in lung 
microvasculature by activating endothelial cell adhesion molecule expression and 
induce migration of PMNs into lung interstitium and alveolar space. Within hours, 
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PMNs propagate inflammation through secretion of reactive oxygen species (e.g., 
hypochlorite), antimicrobial proteins (e.g., bactericidal permeability-inducing protein 
and lactoferrin), and proteolytic enzymes. However, reactive substances secreted 
by PMNs also affect host cells and can damage host tissues contributing to the 
lung pathology in pneumonia. Lung inflammatory response is further characterized 
by delayed recruitment of MPs, especially monocytes that can actively contribute 
to the pathogenesis of both acute and chronic lung inflammatory diseases. To 
control inflammatory lung responses, numerous strategies have been evolved 
such as elaboration of anti-inflammatory mediators like IL-10 and TGF-1 (74, 75). 
For instance IL-10 blocks expression of IL-2, IFN-, IL-1, TNF-, IL-12 and CXC 
and CC chemokines (74). 
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2 AIM OF THE STUDY 
Resident alveolar macrophages are the major mononuclear phagocytic cells found 
in the lower respiratory tract. They act as sentinels for pathogens and their 
components such as LPS and bacterial lipoproteins sensed by TLR4 and TLR2, 
respectively. The signalling pathways activated in alveolar macrophages by 
different TLR agonists have not yet to been fully elucidated. Therefore, in the 
present study we aimed to further explore the molecular programs activated by 
bacterial TLR ligands. In particular, we sought to identify and functionally 
characterize novel mechanisms that regulate alveolar macrophage responses 
induced by TLR4 ligand LPS and TLR2 ligand Pam3CSK4. 
In addition to activation of lung resident cells, alveolar recognition of inhaled 
pathogens promotes increased recruitment of circulating mononuclear phagocytes 
to inflamed tissue. Experimental data on their migration pathways, traffic related 
cell differentiation and functional role in inflamed lungs in vivo are scarce. 
Moreover, compared to the TLR4 ligand LPS a limited number of studies have 
addressed the induction of lung inflammation and the concomitant mononuclear 
phagocyte recruitment in response to TLR2 agonists. Therefore, this study was 
undertaken to analyse the global gene expression profile of mononuclear 
phagocytes recruited from the circulation into TLR2 agonist Pam3CSK4-treated 
inflamed lungs. 
Perspectively, comprehensive insights into the molecular programs induced by 
microbial challenge in pulmonary mononuclear phagocytes may help to identify 
new molecular target for selective therapeutic intervention.  
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Animals 
BALB/c and C57BL/6 WT mice were purchased from Charles River (Sulzfeld, 
Germany). CC3TLR/J BALB/c (TLR4-mutated) mice were purchased from Jackson 
Laboratories (Bar Harbour, USA) and TLR2-KO C57BL/6 mice from Oriental Yeast 
Company (Tagata Shizouka, Japan). PKR-KO C57BL/6 mice were a kind gift of 
Jovan Pavlovic (University of Zurich, Switzerland). CX3CR1GFP/GFP mice were 
generated on a mixed C57BL/6 x 129/Ola background by targeted disruption of 
CX3CR1 gene. Parent CX3CR1GFP/GFP and CX3CR1+/+ mice were bred to yield 
heterozygous CX3CR1+/GFP offspring (76). All animals were kept under specific 
pathogen-free (SPF) conditions and used throughout the study between 8 and 12 
weeks of age. Experimental protocols involving animals were approved by 
institutional and local government comities. 
3.1.2 Equipment 
 
Abbocath Abbott, Germany 
ABI PRISM 2400 PCR-thermocycler Applied Biosystems, USA 
ABI PRISM 7900HT Sequence detector Applied Biosystems, USA 
Agilent Bioanalyser 2100 Agilent Tech., Germany 
BioDocAnalyse video system Whatman – Biometra, Germany 
Cell culture incubator Heraeus, Germany 
Cytospin Cytocentrifuge Thermo Scientific, Germany 
Developing machine, Curix 60 Agfa, Germany 
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Electrophoresis apparatus Keutz, Germany 
ELISA reader Molecular Devices, Germany 
Eppendorf tubes (1.5ml/2 ml) Eppendorf, Germany 
Film cassette Cronex, Germany 
Filter tip Greiner bio-one, Germany 
Filter units  Millipore, USA 
Fluorescence 8 chamber glass slides BD, Germany 
Fluorescence Activated Cell Sorter BD Biosciences, Germany 
Fluorescence microscope Leica, Germany 
GenePix 4100A scanner Axon Instruments, USA 
Mini Protean 3 cell Bio-Rad, USA 
Mini spin centrifuge Heraeus, Germany 
Mini Trans Blot Bio-Rad, USA 
Mouse Whole Genome Agilent Tech., Germany 
Multifuge centrifuge, 1S-R Heraeus, Germany 
NanoDrop ND-1000 Nano Technologies, USA 
PCR tubes (0.2 ml) Applied Biosystems, USA 
Pipetmans: P10, P20, P100, P200, P1000  Gilson, France 
Pipette tip BD, Germany 
Power supply Biometra, Germany 
Serological pipette: 5, 10, 25, 50 ml  Falcon, USA 
Stereomicroscope Leica, Germany 
Test tubes:15, 50 ml Greiner Bio-One, Germany 
Test tube thermostat Roth, Germany 
Tissue culture plates: 24, 48, 96 well Greiner Bio-One, Germany 
  
25 
 
MATERIALS AND METHODS 
 
3.1.3 Kits 
 
BD SMART Probe amplification kit Clontech, Germany 
DC protein assay Bio-Rad, Germany 
ELISA kits  R&D Systems, USA 
Platinum® SYBR® Green I qPCR 
SuperMix-UDG 
Invitrogen, Germany 
RNeasy Micro kit Qiagen, Germany 
RNeasy Mini kit Qiagen, Germany 
Active Motif, Belgium TransAM p65 NF-B assay kit 
 
3.1.4 Reagents 
 
2-AP Sigma-Aldrich, Germany 
5 X first strand buffer Invitrogen, Germany 
Acetic Acid Merck, Germany 
Acetone Sigma-Aldrich, Germany 
Acrylamide solution, Rotiphorese Gel 30 Roth, Germany 
Agarose Peqlab, Germany 
Ammonium persulfate (APS) Promega, Germany 
-mercaptoethanol Sigma-Aldrich, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Germany 
Bromophenol blue Sigma-Aldrich, Germany 
Calibrate beads BD Biosciences, Germany 
DAPI Sigma-Aldrich, Germany 
DifcoTM Skim Milk BD, Germany 
Dithiothreitol (DTT) Invitrogen, Germany 
dNTPs Applied Biosystems, USA 
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Dublecco’ s phosphate buffered saline 
(PBS) 
PAA Laboratories, Austria 
Amersham Biosciences, UK ECL Plus Western Blotting Detection 
System 
E. coli lipopolysaccharide (0111:B4) Calbiochem, Germany 
Ethanol Carl Roth, Germany 
Ethidium bromide solution  Carl Roth, Germany 
Promega, USA Ethylendinitrilo-N, N, N´, N´, -tetra-acetic 
acid (EDTA) 
Ethylene glycol-bis (2-amino-ethylether)-
N,N,N’,N’ –tetra-acetic-acid (EGTA) 
Sigma-Aldrich, Germany 
Fetal calf serum (FCS) PAA laboratories, Austria 
Glycine Sigma-Aldrich, Germany 
Hydrochloric acid (HCl) Merck, Germany 
Igepal CA-630 Sigma-Aldrich, Germany 
Isoflurane (1-chloro-2,2,2-trifluoroethly 
difluoromethyl ether) 
Abbott, Germany 
Ketavet (Ketamine hydrochloride) Pharmacia & Upjohn, Germany 
Methanol  Fluka, Germany 
M-MLV reverse transcriptase Promega, USA 
Mounting medium Dako, Germany 
N,N,N',N'-tetramethyl-ethane-1.2-diamine 
(TEMED) 
Sigma-Aldrich, Germany 
EMC Microcollections, Germany Pam3-Cys-Ser-Lys-Lys-Lys-Lys-OH 
(Pam3CSK4) 
Paraformaldehyde Sigma-Aldrich, Germany 
Penicillin-streptomycin PAA Laboratories, Austria 
Platinum Taq DNA polymerase Invitrogen, Germany 
Polyriboinosinic:polyribocytydylic acid  
(Poly I:C)
Alexis Biochemicals, Germany 
Polyvinylidene difluoride (PVDF) 
membranes  
Micron Separations, USA 
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Precision Plus ProteinTM Standards Bio-Rad, USA 
Protease inhibitor cocktail Roche, Germany 
Random hexamers Boehringer, Germany 
RNase away Molecular Bioproducts, USA 
RNase inhibitor Promega, USA 
Rompun (Xylazine hydrochloride)  Bayer, Germany 
RPMI 1640 medium PAA laboratories, Austria 
Sodium chloride Braun, Germany 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Germany 
Sodium ortho vanadate Sigma-Aldrich, Germany 
Tris Carl Roth, Germany 
Tween 20 Sigma-Aldrich, Germany 
 
3.1.5 Software 
BioConductor http://www.bioconductor.org 
BLAST http://www.ncbi.nlm.nih.gov 
FACS DiVa software BD Biosciences, Germany 
Developed by Dr. Jochen Wilhelm 
(Giessen University) GeneBank Analyzer 
GENECODIS www.genecodis.com 
GenePix Pro 5.0 Axon, USA 
MicroWin 3.0 Microtek, Germany 
Primer Express 2.0 Applied Biosystems, USA 
R software http://www.cran.r-project.org 
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3.2 Methods 
3.2.1 Treatment of animals 
3.2.1.1 Mouse model of TLR2/4 ligands-induced lung inflammation 
In order to study lung inflammatory responses in vivo, WT or CX3CR1+/GFP mice 
received intratracheal (i.t.) application of TLR ligands. Pam3CSK4 was used as a 
synthetic TLR2 agonist recognized by the TLR1/TLR2 complex, whereas LPS 
served as specific TLR4 ligand. Briefly, mice were anesthetized with tetrazoline 
hydrochloride (2.5 mg/Kg) and ketamine (50 mg/Kg) and the trachea was exposed. 
Subsequently, a 26-gauge catheter was inserted into trachea and Pam3CSK4  
(10 μg or 50 μg/mouse dissolved in a total volume of 60 μl) or LPS (1 μg or 10 
μg/mouse dissolved in a total volume of 60 μl) was installed under 
stereomicroscopic control. After installation, the catheter was removed, wounds 
were closed and mice were allowed to recover with free access to food and water.  
3.2.1.2 Collection and analysis of blood and bronchoalveolar lavage (BAL) 
fluid  
Mice were sacrificed with an overdose of isoflurane and blood and BAL fluid 
(BALF) collection was done as described previously (69). Briefly, blood was 
collected from the vena cava inferior using 23-gauge cannula connected to a 1-ml 
insulin syringe that was filled with 100 	l of NaCl-EDTA as an anticoagulant. Lysis 
of red blood cells was performed using ammonium chloride solution.  
For BAL, the trachea was exposed and a small incision was made to insert a 
shortened 21-gauge cannula connected to a 1-ml insulin syringe, followed by 
repeated i.t. instillations of 0.5 ml aliquots of PBS (pH 7,2, supplemented with 2 
mM EDTA). BAL was performed until a total volume of 5 ml was recovered. BALF 
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was spun for 10 min at 1400 rpm at 4 °C and cells were resuspended in 1 ml of 
RPMI 1640 medium containing 10 % FCS and L-glutamine.  
To study the inflammatory BALF profile, the cells were counted with a 
hemocytometer and quantitation of AMs and neutrophils was done on differential 
cell counts of Pappenheim-stained cytocentrifuge preparations as recently 
described (77). 
3.2.1.3 Fluorescence activated cell sorting (FACS) 
Recovered BALF and blood cells were pooled from 10-12 CX3CR1GFP/+ mice to 
obtain sufficient cell numbers for flow sorting. Prior to cell sorting, blood and BALF 
samples were filtered through a 40 μm cell strainer. The GFP-positive MPs were 
counted and sorted using a high-speed FACSVantage SE flow cytometer (BD 
Biosciences) as described previously (69). In short, the sorting algorithm for  
GFP-positive cells employed (1) forward scatter area (FSC-A) versus side scatter 
area (SSC-A), (2) FSC-A versus FL1 (F525 ± 15 nm; FITC/GFP) and (3) FL1  
versus FL2 characteristics (F575 ± 25 nm). These settings allowed for the 
exclusion of lymphocytes, AMs and neutrophils in analyzed samples. The purity of 
sorted GFP-positive cells was 
 98 %. In addition, Pappenheim staining verified 
monocytic cell morphology of isolated GFP-positive cells. Dot plot profiles were 
obtained from 104 cells for each sample. 
3.2.2 Cell culture and stimulation 
3.2.2.1 Culture of murine primary alveolar macrophages 
AMs were harvested by BAL from WT BALB/c, CC3TLR/J, TLR2-KO and PKR-KO 
mice as described in section 3.2.1.2. Cells were cultured in RPMI 1640 medium 
supplemented with 10 % FCS, L-glutamine and penicillin/streptomycin at 37 °C in 
a humidified 5 % CO2 environment. After two hours, cells were washed with RPMI 
1640 to remove non-adherent cells. Macrophages were seeded at 2.5-3 x 105 
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cells/well in 24-well tissue culture plates for western blotting and TransAM assay, 
at 8 x 104 cells/well in 96-well tissue culture plates for ELISA or at 6 x 104 cells/well 
on glass slides for immunofluorescence microscopy. 
AMs were left untreated or stimulated with Pam3CSK4 (2 μg/ml), poly I:C (50 
μg/ml) or LPS (200 ng/ml) for different periods of time as specified. Were indicated, 
AMs were pre-incubated with 4 mM 2-AP for 30 min. 
3.2.3 RNA analysis 
3.2.3.1 Isolation of total RNA 
Total cellular RNA isolation from primary AMs was performed using RNeasy Mini 
Kit. Total cellular RNA from freshly sorted GFP-positive MPs was performed using 
the RNeasy Micro kit. In both the cases, RNA was isolated following the 
instructions of the manufacturer and was quantified spectrophotometrically using 
Nanodrop ND-100. For microarray experiments the RNA quality was assessed by 
the 18S/28S-rRNA bands in capillary electrophoresis.  
3.2.3.2 Microarray analysis 
The microarray experiments were performed in the Department of Pathology 
(University of Giessen) by Dr. Jochen Wilhelm and Marlene Stein. Purified total 
RNA was amplified and Cy-labeled using the SMART™ (switching mechanism at 
the 5' end of RNA templates of reverse transcriptase) kit following the kit 
instructions. Briefly, this method creates full-length complementary DNA (cDNA) 
from all oligo-A RNA with introduced specific primer binding sites at either end. 
One priming site is introduced by the oligo-dT primer and the other one is linked by 
template-switching of the MMLV RT: the RT adds a stretch of Gs to the end of the 
cDNA when the end of the RNA template is reached. A C-rich 
oligodesoxyribonucleotide containing the PCR-primer sequence binds to this 
stretch; the RT then switches the template and produces a sense cDNA strand that 
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now contains the binding site for the PCR primer at either side. These full-length 
cDNAs are subsequently amplified by PCR. In preliminary experiments, the 
number of amplification cycles was determined so that the PCR is not run until the 
plateau. The samples were finally amplified for 24 cycles, followed by 4 cycles with 
aminoallylated dCTP. After purification, monoreactive Cy-dyes were coupled to the 
incorporated amino groups. Cy3- and Cy5-labeled cDNAs were hybridized 
overnight to 44K 60mer oligonucleotide spotted microarray slides. Hybridization 
and subsequent washing and drying of the slides were performed following the 
Agilent hybridization protocol. 
Dried slides were scanned using the GenePix 4100A scanner. Image analysis was 
performed with GenePix Pro 5.0 software, and calculated values for all spots were 
saved as GenePix results files. Stored data were evaluated using the R software 
(http://www.R-project.org) and the limma package from BioConductor (78). The 
spots were weighted for subsequent analyses according to the spot intensity, 
homogeneity, and saturation. The spot intensities were corrected for the local 
background using the method of Edwards with an offset of 64 to stabilize the 
variance of low-intensity spots (79). The M/A data were LOESS normalized before 
averaging (80). Genes were ranked for differential expression using a moderated t-
statistic (81). Candidate lists were created by adjusting the false-discovery rate 
(FDR) to 10 %.  
Raw data was submitted to NCBI Gene Expression Omnibus (GEO) database 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=hpgntswwcowiifq&acc=GSE
11978). 
3.2.3.3 Reverse transcription reaction 
In order to measure messenger RNA (mRNA), reverse transcriptase (RT) was 
used to convert mRNA into cDNA which is then amplified by real-time PCR. To 
perform synthesis of cDNA, 50 ng to 500 ng of total RNA was mixed with random 
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hexamers (10 pmol) in PCR tube, heated at 70 0C for 5 min, placed on ice and the 
following RT mix reaction components were added. 
 
RT mix 
5x first strand buffer 5 μl 
dNTPs 10 mM each 
DTT 250 mM 
Ribonuclease inhibitor 20 U 
MMLV 200 U 
 
Subsequently this mixture was incubated for 1 h at 42 0C, heated to 94 0C for 10 
min to inactivate the enzyme and used for real-time PCR amplification immediately 
or stored at -20 0C till further use. 
3.2.3.4 Quantitative real-time PCR 
The transcriptional regulation of selected genes was analyzed using real-time 
quantitative PCR. Real-time PCR is a method based on the detection and 
quantification of a fluorescent reporter signal that increases in direct proportion to 
the amount of the PCR product in reaction (82, 83). Quantitative real-time PCR 
was performed using SYBR green, a fluorogenic dye that emits a strong 
fluorescent signal upon binding to the minor groove of double-stranded DNA 
product. PCR reactions were performed in 25 	l reactions using the following 
master mix.  
 
Real time master mix 
cDNA 5 μl 
Forward primer 10 pmol 
Reverse primer 10 pmol 
SYBR® Green I 12 μl 
ROX reference dye 0.5 μl 
MgCl2 (50 X) 1 μl 
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Cycling conditions were as following: 1 cycle of 95 °C for 5 min, followed by 45 
cycles of 95 °C for 10 sec, 60 °C for 30 s and 72 °C for 10 sec. After the cycling 
process, melting curve analysis and agarose gel electrophoresis (in selected 
cases) was performed to confirm the exclusive amplification of the expected PCR 
products. Relative gene expression is expressed as Delta Ct (˂CT) with mouse 
porphobilinogen deaminase (PBGD) serving as reference gene: ˂&7 = Ct [PBGD] 
– Ct [target gene] (higher values indicate higer mRNA levels). Differential gene 
expression between conditions is expressed as Delta Delta Ct (˂˂&7) what 
corresponds to the log2 fold-difference in mRNA levels between the conditions 
compared (84). The mRNA sequences of the genes of interest were obtained from 
NCBI http://www.ncbi.nlm.nih.gov/sites/entrez. The oligonucleotide primer pairs 
were designed using Primer Express 2.0. Oligonucleotide primers are listed in 
Appendix (Table 6.1.) 
3.2.4 Protein analysis 
3.2.4.1 Cell extracts and western blotting 
After removing the medium, cells were washed twice with cold 1 x PBS and  
ice-cold cell-lysis buffer was applied. The cell lysates were kept on ice for 30 min, 
followed by centrifugation for 15 min at 13000 rpm at 4 °C. Resulting supernatant 
was used as a crude extract. 
Cell-lysis buffer
20 mM Tris (pH 7.5) 
150 mM NaCl 
1 mM EDTA  
1 mM EGTA 
0.5 % Igepal CA-630 
2 mM Na3VO4
1 X Protease inhibitor mix 
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Protein concentration was determined using Bio-Rad DC (detergent compatible) 
protein assay. This method is a colorimetric reaction similar to the  
well-documented Lowry assay (85). Subsequently, proteins were separated 
according to their size by SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
under reducing and denaturating conditions in 1 x SDS-running buffer (80 V and 
40 mA for 2 h). Gels were composed of a 5 % stacking and a gel 10 % separating 
gel. Before samples were loaded into gel, proteins were mixed with loading buffer 
and heated at 95 °C for 5 min. 
 
10 x Loading buffer
50 mM Tris-HCL 
100 mM DTT 
2% (w/v) SDS 
10% (v/v) Glycerol 
0,1% (w/v) Bromophenol Blue 
 
1 x SDS running buffer 
25 mM Tris base 
250 mM Glycine 
0.1% (v/v) SDS 
 
Stacking gel 5 % 
125 mM Tris (pH 6.8) 
5 % Acrylamid 
0.1% (w/v) SDS 
0.1%(v/v) Temed 
0.1% (w/v) APS 
 
Separating gel 10 % 
375 mM Tris (pH 8.8) 
10 % Acrylamid  
0.1% (w/v) SDS  
0.1%(v/v) Temed 
0.1% (w/v) APS 
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After gel electrophoresis, proteins were transferred to a polyvinylidene difluoride 
(PVDF) membrane using a Bio-Rad transfer chamber containing transfer buffer. 
Transfer was performed at 120 V and 250 mA. After one hour, membranes were 
incubated in blocking buffer at room temperature for 1 h. Subsequently primary 
antibodies were added and membranes were incubated overnight at 4 °C, 
afterwards washed three times and incubated with horse radish peroxidase (HRP)-
conjugated secondary antibody for 1 h. Enhanced Chemiluminescence (ECL) 
system was used to visualize immune complexes. Signals were detected using 
radiographic films. For reprobing, membranes were incubated at room temperature 
for 1 h in stripping buffer. Primary and secondary antibodies used for western 
blotting are listed in Appendix (Table 6.2). 
 
Transfer buffer pH 7.4
25 mM Tris base 
192 mM Glycine 
10 % (v/v) Methanol 
 
Washing buffer (1 L)
100 ml 10 X PBS 
900 ml dH2O 
0.05 % Tween 20 
 
Blocking Buffer  
5 % (w/v) non-fat dry milk 
1 X PBS 
0.05 % Tween 20 
  
Stripping Buffer (100 ml) 
10 ml Glycine (1M) 
89 ml dH2O 
1 ml 37 % HCl 
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3.2.4.2 Enzyme-linked immunosorbent assay (ELISA) 
The quantification of murine TNF- and IL-6 proteins in AM culture supernatants 
was performed by commercially available ELISA kits following the instructions of 
the manufacturer. 
3.2.4.3 Immunofluorescence microscopy 
Cells were washed twice with 1 x PBS and fixed with cold (-20 °C) 
methanol:acethone mixture (1:1) for 10 min. After washing, cells were blocked 
overnight with 10 % BSA in PBS, washed twice and then incubated overnight with 
rabbit anti-p65 NF-B antibody (1:50) diluted in 1 % BSA at 4 °C. Immune 
complexes were detected with Alexa Fluor 488 goat anti-rabbit secondary antibody 
diluted in 1 % BSA (1:1000) at room temperature for 1 h in darkness. After 
washing, cells were fixed in 4 % paraformaldehyde for 10 min. Nuclei were stained 
with DAPI (1:100) diluted in 1 % BSA. The coverslips were mounted on slides in 
mounting medium. Cells were imaged by conventional fluorescence microscopy. 
Primary and secondary antibodies used for immunofluorescence microscopy are 
listed in Appendix (Table 6.2). 
3.2.4.4 TransAM p65 NF-B assay  
Whole cell extract (5 μg) was used to monitor activation of the p65 subunit of  
NF-B by the commercially available TransAM p65 NF-B assay kit purchased 
from Active Motif following the instructions of manufacturer. 
3.2.5 Statistical analysis 
The data for BALF cell profile are presented as mean ± SD. Differences between 
treatments groups were analysed by one-way ANOVA followed by Dunnett post
hoc test. A value of p  0.05 was considered as significant. Ct and Ct values 
are given as mean ± SD or SEM of at least three independent experiments. 
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Differences in mean Ct values were tested by two-tailed (paired or unpaired)  
t-tests. A value of p  0.05 was considered significant. 
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4 RESULTS 
4.1 Gene expression of TLR associated proteins induced 
by inflammatory stimuli in AMs 
Initial experiments aimed to analyse the transcriptional regulation of genes 
involved in TLRs signalling in response to bacterial components that are 
differentially recognized by distinct TLR family members. We used synthetic 
lipoprotein Pam3CSK4 that is specifically recognized by the TLR1/2 complex, 
whereas LPS derived from Escherichia coli was used as specific ligand for TLR4 
(86). Genes selected for evaluation belonged to different functional categories: 
PRRs (CD14, CD36, TLR2 and TLR4), cytokine regulators (SOCS 1/3), 
inflammatory cytokines (TNF-, IL-6), antiviral defence and negative regulators of 
TLRs (IRAK-M, ST2 and SIGIRR). The full names of genes are presented in table 
4.1. 
AMs isolated from BALF of WT BALB/c mice were left either untreated or 
stimulated with the TLR2 ligand Pam3CSK4 or the TLR4 ligand LPS. Using 
quantitative real-time PCR, we found that both ligands induced comparable 
changes in the expression profile of TLR molecules after 6 h and 24 h in vitro 
(Table 4.1). Transcription of two PRRs, TLR2 and CD14 was significantly 
increased, whereas expression of TLR4 and CD36 mRNA remained unchanged 
after treatment with both ligands. Most drastic changes in mRNA levels were noted 
for the pro-inflammatory cytokines IL-6 and TNF- and for SOCS proteins. 
Interestingly, transcription of dsRNA-activated protein kinase R (PKR), the antiviral 
defence molecule, was significantly increased in response to Pam3CSK4 and LPS 
ligands. Among negative regulators, IRAK-M mRNA was significantly up-regulated 
after treatment with both TLR ligands, whereas ST2 was induced only by the TLR2 
ligand after 6 h. 
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Table 4.1 mRNA expression of TLR associated genes in cultured AMs 
Primary AMs isolated from WT mice were stimulated with LPS or Pam3CSK4 for 6 h or 24 h. After 
RNA isolation, the relative amount of each mRNA gene transcript was determined using real-time 
PCR. Relative gene expression was calculated using the CT method as described in Materials 
and Methods. Positive values indicate up-regulation of that particular gene, whereas negative 
values indicate the down-regulation of a given gene. The results are given as mean ± SD from 
three independent experiments. * indicates P at least < 0.05. 
 
Gene symbol Gene description
6h 24h 6h 24h
CD14 CD 14 antigen *2.7±0.6 *3.3±0.6 *2.7±0.4 *2.9±0.4
CD36 CD 36 antigen 0.2±0.4 –1.3±0.3 0.2±0.3 –0,8±0.3
TLR2 Toll-like receptor 2 *2.4±0.2 *3.5±0.2 *1.6±0.1 1.7±0.5
TLR4 Toll-like receptor 4 0.1±0.5 *0.6±0.1 0.3±0.4 0.0±0.2
SOCS-1 Suppresor of cytokine signalling 1 *4.6±1.1 *4.1±0.8 *3.3±0.2 *4.7±0.1
SOCS-3 Suppresor of cytokine signalling 3 *4.7±0.2 *3.8±0.2 *4.5±0.1 *3.7±0.3
TNF- Tumor necrosis factor alpha *3.4±0.4 –0.6±0.4 *2.7±0.4 0.4±0.5
IL-6 Interleukin 6 *10.0±2.1 *7.8±2.1 *9.8±0.2 *9.1±0.5
PKR Protein kinase R *3.0±0.5 *2.2±0.2 *1.7±0.3 *1.6±0.3
IRAK-M Interleukin-1 receptor-associated kinase M *1.8±0.1 *2.4±0.2 *2.1±0.4 *2.5±0.3
ST2 Interleukin 1 receptor-like 1 0.4±0.7 –0.2±0.5 *1.4±0.5 0.2±0.8
SIGGIR Single immunoglobulin domain IL-1R-related –1.7±0.3 0.5±0.4 –1.5±0.3 –0.5±0.6
CT±SD
Pam3CSK4LPS
 
 
To study regulation of TLRs and associated signalling molecules in the alveolar 
space under in vivo conditions, WT BALB/c mice were i.t. administrated with 
Pam3CSK4 (10 μg/mouse) or LPS (1 μg/mouse). Subsequently, AMs were 
separated by high-speed FACSDiva flow cytometry as described in Materials and 
Methods (Figure 4.1). After sorting, total RNA was isolated and subjected to 
quantitative real-time PCR. We observed that gene expression patterns from in 
vitro experiments largely matched with in vivo data (Table 4.2). Interestingly, AMs 
expressed significantly more PKR mRNA after LPS administration, whereas there 
was no increase of PKR mRNA after i.t. Pam3CSK4 administration. Based on these 
results and data from the literature we decided to analyze in detail the role of PKR 
in AMs in response to bacterial TLR ligands.
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Figure 4.1 Flow cytometric identification and separation of AMs of untreated and LPS treated 
WT mice 
(A) A representative FACS profile of BALF cells collected from WT mice either left untreated (left
column) or intratracheally administrated with LPS (1 μg/mouse) (right column). AMs were gated 
according to the forward scatter area (FSC-A) vs. side scatter area (SSC-A) (P1), FSC-A vs. 
fluorescence 1 area (FL1-A, FITC-A) (gate P2) and FL1-A vs. fluorescence 2 area (FL2-A, PE) 
(gate P3, green high auto-fluorescent AMs). (B) Pappenheim-stained cytospins of BALF cells 
isolated from LPS-treated mice prior to sorting (upper photomicrograph) and after sorting (bottom
photomicrograph). 
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Table 4.2 mRNA expression of TLR associated genes in flow-sorted AMs 
Gene expression profiles of selected genes in flow-sorted AMs collected from WT mice 
intratracheally administrated with LPS or Pam3CSK4 for 6 h or 24 h. After RNA isolation, the relative 
expression of each mRNA gene transcript was determined using real-time PCR. Relative gene 
expression was calculated using the CT method as described in Materials and Methods. Positive 
values indicate up-regulation of that particular gene, whereas negative values indicate the  
down-regulation of a given gene. The results are given as mean ± SD from three independent 
experiments. * indicates P at least < 0.05. 
 
Gene symbol Gene description
6h 24h 6h 24h
CD14 CD 14 antigen 4.2±1.5 2.1±0.8 2.4±1.4 1.8±0.5
CD36 CD 36 antigen 0.5±0.4 0.5±0.5 1.6±0.7 0.6±0.8
TLR2 Toll-like receptor 2 *2.8±0.2 0.7±0.2 *2.2±0.1 0.6±0.7
TLR4 Toll-like receptor 4 –0.4±0.3 –0.5±0.5 –0.4±0.8 –0.5±0.6
SOCS-1 Suppresor of cytokine signalling 1 *3.6±1.6 *1.9±0.6 1.8±0.9 *2.0±0.6
SOCS-3 Suppresor of cytokine signalling 3 *5.9±0.8 *3.4±0.9 *4.7±1.1 3.2±1.1
TNF- Tumor necrosis factor alpha *5.6±1.2 1.8±0.8 *4.3±1.8 2.4±0.8
PKR Protein kinase R *3.0±0.9 0.0±0.2 0.0±0.5 0.0±0.4
IRAK-M Interleukin-1 receptor-associated kinase M *3.2±0.8 1.3±0.5 2.5±0.6 1.9±0.5
CT±SD
Pam3CSK4LPS
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4.2 Role of PKR in TLR2/4 signalling in murine AMs  
4.2.1 PKR protein expression after stimulation with TLR2/4 
ligands 
To determine the regulation of PKR protein expression after PAMP stimulation we 
used western blotting. In agreement with the observations on mRNA expression 
levels, PKR protein expression was increased after both Pam3CSK4 and LPS 
stimulation in vitro (Figure 4.2). 
 
0 12 24 0 12 24
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PKR
-actin
 
 
Figure 4.2 PKR protein accumulation after stimulation with TLR ligands 
WT AMs were stimulated with either Pam3CSK4 (2 	g/ml) or LPS (200 ng/ml) for the indicated time 
intervals. Cells lysates were resolved on SDS-PAGE and probed with anti-PKR antibody as 
described in Materials and Methods. Anit--actin antibody served as loading control. The data are 
representative of two independent experiments. 
4.2.2 Induction of PKR phosphorylation by TLR2/4 ligands  
Since PKR phosphorylation is necessary for its activation, we examined whether 
PKR is phosphorylated in murine primary AMs after stimulation with TLR ligands in
vitro. Isolated AMs were left untreated or stimulated with Pam3CSK4 or LPS for 
indicated time intervals and PKR phosphorylation was evaluated by western 
blotting. PKR was found to be activated by both TLR ligands within 15 min, 
reaching maximum phosphorylation levels at 30 min after stimulation (Figure 4.3).
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Figure 4.3 Time-course analysis of PKR phosphorylation  
WT AMs were stimulated with Pam3CSK4 (2 	g/ml) or LPS (200 ng/ml) for the indicated time 
intervals. Cells lysates were resolved on SDS-PAGE and probed with anti-phospho PKR and anti-
PKR antibodies as described in Materials and Methods. The data are representative of three 
independent experiments.  
 
To elucidate whether Pam3CSK4 and LPS-induced activation of PKR was 
dependent on specific binding to the respective TLR, we isolated AMs from  
TLR2-deficient (TLR2-KO) and TLR4 mutated mice (CC3TLR/J). Cells were 
stimulated with LPS, Pam3CSK4 or poly I:C (synthetic dsRNA) for 30 min and PKR 
phosphorylation was assessed by western blotting (Figure 4.4). No activation of 
PKR was observed after stimulation with LPS and Pam3CSK4 in TLR4 mutated 
and TLR2-KO cells, respectively. As expected, poly I:C triggered PKR activation in 
WT, TLR2-KO and TLR4-mutated macrophages. Taken together, these results 
demonstrate that not only TLR4 but also TLR2 ligands are capable to induce PKR 
phosphorylation in AMs. Moreover this activation was strictly dependent on the 
functionality of the respective TLR. 
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Figure 4.4 Activation of PKR by PAMPs is TLR dependent  
AMs isolated from WT, TLR2-KO and CC3TLR/J mice were left untreated or stimulated with LPS 
(200 ng/ml), Pam3CSK4 (2 	g/ml) or Poly I:C (50 	g/ml) for 30 min. Cells lysates were resolved on 
SDS-PAGE and probed with anti-phospho PKR and anti-PKR antibodies as described in Materials 
and Methods. The data are representative of two independent experiments.  
 
To investigate further the role of PKR kinase activity in TLR2/4 signalling, we 
applied 2-aminopurine (2-AP), a widely used specific inhibitor for PKR 
phosphorylation. 2-AP is acting as a competitive inhibitor of adenosine 
triphosphate (ATP) during the autophosphorylation of activated PKR (87).  
Pre-treatment of AMs with the PKR inhibitor 2-AP (4 mM) for 30 min prior to 
stimulation with the respective TLR agonist, drastically reduced PKR 
phosphorylation but also resulted in down-regulation of PKR mRNA levels (Figure 
4.5). 
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Figure 4.5 Pharmacological inhibition of PKR phosphorylation by 2-AP  
WT AMs were stimulated with Pam3CSK4 (2 	g/ml) or LPS (200 ng/ml) for the indicated time 
intervals and the effect of 2-AP on PKR activation and expression was evaluated. (A) Cells lysates 
were resolved on SDS-PAGE and probed with anti-phospho PKR and anti-PKR antibodies as 
described in Materials and Methods. The data are representative of three independent 
experiments. (B) 2-AP effect on PKR mRNA was analysed by real-time quantitative PCR as 
described in Materials and Methods. Data are represented as mean ± SD of three independent 
experiments. 
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4.2.3 Involvement of PKR in PAMP-induced release of 
inflammatory cytokines 
Induction of TLR signalling by PAMP binding to the respective receptor ultimately 
leads to pro-inflammatory cytokine secretion. To evaluate whether PKR activation 
is required for TLR2 and TLR4 mediated cytokine release, WT AMs in the 
presence or absence of the PKR inhibitor 2-AP and PKR-KO AMs were stimulated 
with LPS or Pam3CSK4 for 6 h (Figure 4.6). 
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Figure 4.6 PAMP-induced inflammatory cytokine secretion requires PKR phosphorylation  
AMs from WT or PKR-KO mice were incubated with medium alone or with 2-AP (4 mM) for 30 min 
followed by stimulation with LPS (200 ng/ml) or Pam3CSK4 (2 	g/ml) for 6 h. Collected supernatants 
were assayed for TNF- (A) and IL-6 (B) concentrations by ELISA as described in Materials and 
Methods. Data are represented as mean ± SD of at least three independent experiments. 
 * indicates P at least < 0.01. 
  
WT cells pre-treated with 2-AP as well as PKR-KO cells displayed a significantly 
reduced PAMP-induced release of TNF- and IL-6 as assessed by ELISA in the 
supernatant. These data indicate that PKR phosphorylation is critically involved in 
TLR2 and TLR4 mediated cytokine secretion by AMs. 
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4.2.4 Role of PKR in NF-B activation  
PAMP-induced production of TNF- and IL-6 is dependent on the activation of 
transcription factors such as NF-B. To assess whether the activation of NF-B 
following TLR2 or TLR4 signalling depends on PKR phosphorylation, WT AMs in 
the presence or absence of 2-AP and PKR-KO AMs were stimulated with LPS or 
Pam3CSK4. Activation of the p65 subunit of NF-B was determined with a NF-B 
p65 ELISA-based assay. p65 activation induced by LPS was found to be 
significantly reduced after pre-treatment with 2-AP. Correspondingly, LPS induced 
p65 NF-B signalling was found to be significantly attenuated in  
PKR-KO AMs (Figure 4.7 A). In contrast, p65 activation elicited by the TLR2 
agonist Pam3CSK4 stimulation was only slightly impaired by pre-treatment of WT 
AMs with 2-AP or in PKR-KO cells (Figure 4.7 B).  
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Figure 4.7 Pam3CSK4-induced activation of NF-B is PKR-independent  
AMs from WT or PKR-KO mice were incubated with medium alone or with 2-AP for 30 min followed 
by stimulation with LPS (200 ng/ml) for 1 h (A) or with Pam3CSK4 (2 	g/ml) for 2 h (B). Activation of 
p65 subunit of NF-B was monitored in whole cell extracts (5 μg) using the ELISA-based TransAM 
NF-B kit assay as described in Materials and Methods. Results are presented as mean ± SD of at 
least three different experiments. * indicates P at least < 0.05. TransAM assay specificity was 
monitored using nuclear extracts isolated from Jurkat cells as described in Appendix (Figure 6.2). 
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Figure 4.8 Immunofluorescence microscopy of p65 nuclear translocation 
AMs from WT mice were incubated with medium alone or with 2-AP for 30 min followed by 
stimulation with LPS (200 ng/ml) for 1 h or with Pam3CSK4 (2 	g/ml) for 2 h. After washing, cells 
were stained with primary rabbit antibody against p65, followed by incubation with a secondary 
Alexa fluor 488 labeled goat anti-rabbit Ig antibody (green) as described in Materials and Methods. 
Nuclei were counterstained with DAPI (blue). The cells were imaged by conventional microscopy. 
Images are representative of three independent experiments. Secondary antibody control is 
presented in Appendix (Figure 6.3).
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To confirm this differential effect of PKR phosphorylation inhibition on TLR2 vs. 
TLR4 mediated NF-B activation, we examined PAMP-induced nuclear 
translocation of p65 by immunofluorescence microscopy (Figure 4.8). In untreated 
AMs, p65 was localized exclusively in the cytoplasm, following stimulation with 
LPS or Pam3CSK4, p65 translocated to the nucleus. 2-AP pre-treatment caused a 
significant reduction of p65 nuclear translocation after LPS but not after Pam3CSK4 
stimulation. Together, these results suggest that PKR phosphorylation plays a 
major role in LPS but not Pam3CSK4-induced activation of the p65 NF-B subunit.  
4.2.5 The role of PKR in MAPKs signalling pathway 
Previous studies have demonstrated that PKR mediates activation of MAPKs in 
response to inflammatory stimuli in various cell types (88-90). Therefore we aimed 
to delineate the role of PKR in this process in AMs. PKR inhibitor 2-AP and AMs 
deficient in functional PKR were used to describe the role of PKR in MAPKs 
activation. We found that only JNK phosphorylation was affected by 
pharmacological suppression of PKR activity and in PKR-KO AMs (Figure 4.9).  
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Figure 4.9 PKR regulates the TLR2/4 ligand-induced JNK signalling pathway 
MAP kinases activation was evaluated in WT AMs incubated with medium alone or with 2-AP for 30 
min (A) or in AMs derived from PKR-KO mice (B). Cells were stimulated with Pam3CSK4 (2 	g/ml) 
or LPS (200 ng/ml) for 30 min. Subsequently, cells lysates were resolved on SDS-PAGE and 
analyzed for MAP kinases phosphorylation using antibodies against phospho-JNK, phospho-p38, 
phospho-ERK1/2, total JNK, total 38 and total ERK as described in Materials and Methods. 
 
To further confirm the role of PKR in the JNK signalling pathway, we tested the 
effect of 2-AP on the regulation of MKK4, a kinase upstream of JNK, and on the 
downstream JNK target c-Jun. Inhibition of PKR markedly reduced 
phosphorylation of MKK4 and strongly decreased c-Jun phosphorylation as 
assessed by mobility shift (Figure 4.10). Collectively, our data indicate that PKR 
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regulates the JNK signalling pathway (PKR-MKK4-JNK-c-Jun) in AMs activated by 
TLR2 or TLR4 ligands. 
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Figure 4.10 PKR regulates JNK signalling pathway via MKK4 
WT AMs were incubated with medium alone or with 2-AP for 30 min, followed by stimulation with 
Pam3CSK4 (2 	g/ml) (A) or LPS (200 ng/ml) (B) for 30 min. Cells lysates were resolved on  
SDS-PAGE and analyzed for JNK pathway activation using antibodies against phospho-MKK4 and 
total c-Jun as described in Materials and Methods. Anti--actin antibody served as loading control. 
Arrow indicates the mobility shift of phosphorylated c-Jun. Data are representative of three 
independent experiments. 
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4.3 Genome-wide transcriptional profiling of MPs 
recruited to mouse lungs in response to alveolar 
challenge with the TLR2 agonist Pam3CSK4 
4.3.1 Induction of lung inflammation and alveolar trafficking of 
circulating MPs by intratracheal deposition of Pam3CSK4 
To determine the capacity of the synthetic TLR2 agonist Pam3CSK4 to induce lung 
inflammation in vivo, WT C57Bl/6 mice received i.t. application of Pam3CSK4 (50 
μg/mouse) and BALF cellular constituents were monitored at various time points 
post challenge. Pulmonary administration of Pam3CSK4 provoked rapid recruitment 
of neutrophils into the alveolar compartment that was detectable as early as at 6 h, 
peaked at approximately 24 h after challenge and significantly declined within the 
next 24 h. The number of BALF macrophages was found to be slightly increased at 
24 h post challenge without reaching statistical significance (Figure 4.11).  
To further assess alveolar trafficking of MPs we employed transgenic CX3CR1+/GFP 
mice expressing green fluorescence protein (GFP) under control of the CX3CR1 
promoter as described before (69, 76). This approach allowed identifying and 
further high purity sorting of GFP-positive MPs from the peripheral blood and of 
freshly recruited MPs from BALF as described in Materials and Methods. 
Heterozygous CX3CR1+/GFP mice were either left untreated or received i.t. 
application of the TLR2 ligand Pam3CSK4 (50 μg/mouse) and recruited MPs 
numbers were assessed in BALF after 24 h or 48 h. Very few GFP-positive cells 
(0.3 %-0.5 %) were detected in BALF collected from untreated mice (Figure. 4.12). 
In contrast, at 24 h and even more pronounced at 48 h after Pam3CSK4 i.t. 
application we observed significantly increased proportions of GFP-positive cells in 
BALF samples (1.4-1.7 % and 2.5-3.5 %, respectively). These data demonstrate 
that i.t. application of the TLR2 ligand Pam3CSK4 induced enhanced trafficking of 
circulating MPs into the alveolar space.  
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Figure 4.11 Inflammatory cell accumulation in the bronchoalveolar compartment in response 
to alveolar deposition of Pam3CSK4
C57BL/6 WT mice were either left untreated (0 h) or were challenged intratracheally with 
Pam3CSK4 (50 μg/mouse) for 6h, 12h, 24h, or 48 h. After indicated times, BALF cells were isolated 
and microscopic differentiation and quantification of macrophages and alveolar recruited 
neutrophils were performed as described in Materials and Methods. Means of different time points 
(five mice per treatment group) were compared using the ANOVA test as described in Materials 
and Methods. * indicates P at least < 0.01.  
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Figure 4.12 Lung recruitment of MPs in the absence or presence of the Pam3CSK4
A representative FACS profile of BALF cells collected from CX3CR1+/GFP mice either left untreated 
(left column) or i.t. administrated with Pam3CSK4 (50 μg/mouse) for 24 h (middle column) or 48 h 
(right column). At the indicated time points, mice were sacrificed and BALF and blood (not shown) 
were collected followed by fluorescence activated cell sorting of peripheral blood and alveolar MPs 
as described in Materials and Methods. Briefly, alveolar MPs were gated according to forward 
scatter area (FSC-A) vs. side scatter area (SSC-A) (R1, living cells), FSC-A vs. fluorescence 1 area 
(FL1-A, FITC-A) (gate R2, GFP positive MPs) and FL1-A vs. fluorescence 2 area (FL2-A, PE-A) 
(gate R3, GFP-positive MPs among R2). Data show one representative of four independent 
experiments. 
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4.3.2  Genome-wide transcriptional profiling of MPs recruited to 
the alveolar space after pulmonary challenge with 
Pam3CSK4 
To investigate global changes in the gene expression profiles of MPs recruited to 
Pam3CSK4 exposed lungs during maximal inflammation (24 h), 10 to 12 
heterozygous CX3CR1+/GFP mice received i.t. application of the TLR2 ligand 
Pam3CSK4 (50 μg/mouse). Twenty four hours post challenge, GFP-expressing 
MPs were isolated in high purity from both PB and BALF and comparative global 
gene expression profiles of PB and alveolar recruited MPs were determined using 
SMART amplification method and whole mouse genome oligonucleotide arrays.  
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Figure 4.13 Global gene expression differences of alveolar recruited vs. PB MPs  
after i.t. application of Pam3CSK4  
The plot shows the average log2 signal ratio (M values) plotted against the average log2 of the spot 
intensity (A values). Positive (negative) M values indicate an up (down)-regulation upon alveolar 
recruitment. The black dots mark candidate genes identified as differentially regulated by a 
moderated t-test using a false-discovery rate of 10 %. 
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We found that the global transcriptome of MPs recruited to the alveolar 
compartment at 24 h in response to Pam3CSK4 was dramatically changed in 
comparison to circulating MPs obtained at the same time point (Figure 4.13). 
Approximately 3700 genes differentially expressed between PB and alveolar 
recruited MPs were identified (10 % FDR) and the majority of which (~2500) were 
up-regulated in the alveolar MP cell population. This group contains a broad panel 
of genes encoding pro-inflammatory cytokines previously described to be robustly 
up-regulated by different microbial components in various cell types such as 
interleukin IL-1, TNF-, IL-6, and IL-12A (Table 4.3). We additionally observed 
up-regulated mRNA levels of chemokines such as KC, CXCL11, CXCL12, 
CXCL13, CXCL16, CCL2 and CCL7, whereas the gene expression of the 
neutrophil and monocyte chemoattractant CXCL7 was significantly down-regulated 
in alveolar mononuclear phagocytes.  
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Table 4.3 Differential gene expression between alveolar recruited and PB MPs 
Gene symbol Accesion No. Gene description Coefficients SEM p-value
Anti-inflammatory genes 
IL1RN NM_031167 Interleukin 1 receptor antagonist 2,5 0,44 0,003
FPR1 NM_013521 Formyl peptide receptor 1 1,7 0,20 <0,001
ADORA2B NM_007413 Adenosine A2b receptor 1,6 0,14 <0,001
IRAKM NM_028679 Interleukin-1 receptor-associated kinase M 1,6 0,05 <0,001
ANXA1 NM_010730 Annexin 1 1,1 0,13 <0,001
BAX NM_007527 Bcl2-associated X protein 1,1 0,13 <0,001
Il18BP NM_010531 Interleukin 18 binding protein 0,7 0,08 <0,001
IL10 NM_010548 Interleukin 10 0,7 0,15 0,014
Eicosanoids metabolism
PTGES NM_022415 Prostaglandin E synthase 2,0 0,36 0,003
LTC4S NM_008521 Leukotriene C4 synthase 1,6 0,33 0,006
LTB4DH NM_025968 Leukotriene B4 12-hydroxydehydrogenase 0,9 0,11 <0,001
COX2 NM_011198 Cyclooxygenase 2 0,7 0,12 0,002
HPGD NM_008278 Hydroxyprostaglandin dehydrogenase 15 -1,5 0,30 0,005
ALOX12 NM_007440 Arachidonate 12-lipoxygenase -1,7 0,24 0,003
Cytokines and chemokines
IL1A NM_010554 Interleukin 1 alpha 2,9 0,36 <0,001
CXCL16 NM_023158 Chemokine (C-X-C motif) ligand 16 2,8 0,40 0,002
TNF NM_013693 Tumor necrosis factor 2,3 0,30 <0,001
IL12A NM_008351 Interleukin 12a 1,8 0,20 <0,001
IGF1 NM_010512 Insulin-like growth factor 1, transcript variant 1 1,6 0,22 <0,001
CCL3 NM_011337 Chemokine (C-C motif) ligand 3 1,6 0,07 <0,001
CCL2 NM_011333 Chemokine (C-C motif) ligand 2 1,0 0,15 0,004
IL6 NM_031168 Interleukin 6 0,9 0,13 <0,001
IL12B NM_008352 Interleukin 12b 0,8 0,18 0,006
IL1B NM_008361 Interleukin 1 beta 0,6 0,14 0,006
CXCL7 NM_023785 Chemokine (C-X-C motif) ligand 7 -2,1 0,30 <0,001
Anti-oxidative
PRDX1 NM_011034 Peroxiredoxin 1 1,4 0,29 0,006
PRDX6 NM_007453 Peroxiredoxin 6 1,2 0,11 <0,001
GSTM1 NM_010358 Glutathione S-transferase, mu 1 1,2 0,23 0,004
GSTT3 NM_133994 Glutathione S-transferase, theta 3 1,2 0,14 <0,001
GSTT2 NM_010361 Glutathione S-transferase, theta 2 1,2 0,12 <0,001
SOD3 NM_011435 Superoxide dismutase 3, extracellular 1,1 0,11 <0,001
GSTM5 NM_010360 Glutathione S-transferase, mu 5 0,8 0,12 <0,001
GCLC NM_010295 Glutamate-cysteine ligase, catalytic subunit 0,4 0,05 <0,001
Migration
ITGA5 NM_010577 Integrin alpha 5 1,6 0,18 <0,001
AQP9 NM_022026 Aquaporin 9 0,9 0,20 0,006
Membrane receptors
CD200R1 NM_021325 CD200 receptor 1 1,7 0,244 0,001
GPR31C NM_001013832 G protein-coupled receptor 31 1,4 0,24 0,002
GPR137B NM_031999 G protein-coupled receptor 137B 1,3 0,13 <0,001
IL11RA NM_010549 Interleukin 11 receptor, alpha chain 1 1,2 0,14 <0,001
GPR84 NM_030720 G protein-coupled receptor 84 1,2 0,16 0,002
GPR178 NM_001033178 G protein-coupled receptor 178 1,0 0,12 <0,001
GIT1 NM_001004144 G protein-coupled receptor kinase-interactor 1 0,5 0,08 0,002
GPR89 NM_026229 G protein-coupled receptor 89 0,5 0,05 <0,001
GPR137 NM_207220 G protein-coupled receptor 137 -0,3 0,07 0,008
GPR34 NM_011823 G protein-coupled receptor 34 -0,4 0,07 0,002
M-CSFR (CD115) NM_007779 Colony stimulating factor 1 receptor -0,6 0,09 0,002
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Gene symbol Accesion No. Gene description Coefficients SEM p-value
Il10RA NM_008348 Interleukin 10 receptor, alpha -0,9 0,13 <0,001
Anti-microbial
LCN2 NM_008491  Lipocalin 2 1,9 0,20 <0,001
Proteases
CTSL NM_009984 Cathepsin L 1,8 0,11 <0,001
CTSZ NM_022325 Cathepsin Z 1,5 0,30 0,005
CTSC NM_009982 Cathepsin C 1,5 0,19 <0,001
CTSB NM_007798 Cathepsin B 0,7 0,10 <0,001
CTSS NM_021281 Cathepsin S 0,6 0,13 0,005
Apoptosis
P2RX4 NM_011026 Purinergic receptor P2X, ligand-gated ion channel 4 2,5 0,09 <0,001
CFLAR NM_009805 CASP8 and FADD-like apoptosis regulator 1,7 0,17 <0,001
BCL2L11 NM_207680 BCL2-like 11 1,4 0,17 <0,001
FAS NM_007987 TNF receptor superfamily, member 6 1,1 0,22 0,006
CD40 NM_170701 CD40 antigen, transcript variant 3 0,7 0,08 <0,001
Pattern recognition receptors
CLEC4N NM_020001 C-type lectin domain family 4, member n 2,4 0,32 <0,001
SR-A NM_031195 Macrophage scavenger receptor SR-AI/II 2,1 0,24 <0,001
CLEC4E NM_019948 C-type lectin domain family 4, member e 1,8 0,26 <0,001
CD14 NM_009841 CD 14 antigen 1,7 0,28 0,002
CLEC4D NM_010819 C-type lectin domain family 4, member d 1,6 0,21 <0,001
CLEC5A NM_001038604 C-type lectin domain family 5, member a 1,5 0,16 <0,001
STAB1 NM_138672 Stabilin 1 1,5 0,29 0,004
TLR2 NM_011905 Toll-like receptor 2 1,3 0,15 <0,001
NOD1 NM_009251 nucleotide-binding oligomerization domain containing 1 -0,8 0,09 0,002
CLEC2I NM_020257 C-type lectin domain family 2, member i -1,0 0,10 0,001
CLEC1B NM_019985 C-type lectin domain family 1, member b -1,3 0,14 <0,001
Complement
CFB NM_008198 Complement factor B 2,1 0,20 <0,001
C3AR1 NM_009779 Complement component 3 receptor 1 2,1 2,06 <0,001
C5AR1 NM_007577 Complement component 5 receptor 1 1,3 0,13 <0,001
C1QB NM_009777 Complement component 1, q subcomponent 1,0 1,40 0,002
C3 NM_009778 Complement component 3 0,6 0,67 0,007
Activated macrophages 
SPP1 NM_009263 Secreted phosphoprotein 1 2,3 0,37 0,002
FN1 NM_010233 Fibronectin 1,8 0,12 <0,001
ARG1 NM_007482 Arginase 1 1,7 0,22 <0,001
TGFI NM_009369 Transforming growth factor, beta induced 1,3 0,14 <0,001
Transporters and channels
SLC9A4 NM_177084 Solute carrier family 9, member 4 2,5 0,55 0,007
ATP6V1C1 NM_025494 ATPase, H+ transporting, lysosomal V1 subunit C1 2,2 0,16 <0,001
SLC25A4 NM_007450 Solute carrier family 25, member 4 0,9 0,08 <0,001
SLC7A11 NM_011990 Solute carrier family 7, member 11 0,9 0,07 <0,001
DNA-binding
ATF3 NM_007498 Activating transcription factor 3 1,7 0,24 <0,001
BATF NM_016767 Basic leucine zipper transcription factor, ATF-like 1,1 0,15 <0,001
ZFP238 NM_013915 zinc finger protein 238 0,8 0,06 <0,001
ZFHX1B NM_015753 zinc finger homeobox 1b 0,7 0,09 0,002
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Gene symbol Accesion No. Gene description Coefficients SEM p-value
ATF5 NM_030693 Activating transcription factor 5 0,6 0,09 0,003
IRF5 NM_012057 Interferon regulatory factor 5 -0,7 0,08 <0,001
GATA1 NM_008089 GATA binding protein 1 -1,1 0,09 <0,001
Phagocytosis
FCGR2B NM_010187 Fc receptor, IgG, low affinity IIb 1,7 0,16 <0,001
FCGR3 NM_010188 Fc receptor, IgG, low affinity III 1,2 0,16 <0,001
FCGR1 NM_010186 Fc receptor, IgG, high affinity I 0,8 0,19 0,009
FCER1G NM_010185 Fc receptor, IgE, high affinity I, gamma polypeptide 0,4 0,07 0,002
CLEC7A NM_020008 C-type lectin domain family 7, member a (Clec7a) -0,9 0,19 0,006
Annexins
ANXA4 NM_013471 Annexin 4 2,2 0,26 <0,001
ANXA5 NM_009673 Annexin 5 1,5 0,33 0,007
ANXA8 NM_013473 Annexin 8 1,4 0,17 0,002
ANXA2 NM_007585 Annexin 2 0,9 0,15 0,003
ANXA7 NM_009674 Annexin 7 0,7 0,10 0,001
 
 
The table illustrates selected genes with differential gene expression between alveolar recruited 
and PB MPs according to the biological interest. The coefficients correspond to the log2 fold 
changes. P values are adjusted for multiple testing by the method of Benjamini and Hochberg. 
Positive coefficients values in the columns indicate mean fold up-regulation of that particular gene 
in alveolar MPs in comparison to PB MPs, whereas negative values indicate mean fold down-
regulation of the respective gene in alveolar MPs as compared to PB MPs. 
 
Notably, this Pam3CSK4-elicited pro-inflammatory activation in freshly alveolar 
recruited MPs coincided with pronounced induction of anti-inflammatory mediators 
such as IL-1RN, IRAK-M and IL-10. Other up-regulated genes related to limitation 
and resolution of inflammation were formyl peptide receptor 1 (FPR-1), IL-18 
binding protein (IL-18BP), adenosine A2b receptor (ADORA2B), annexin 1 (ANXA-
1) and Bcl2-associated X protein (BAX). Moreover, alveolar MPs recruited after i.t. 
Pam3CSK4 application contained elevated mRNA levels of genes associated with 
an alternative activated macrophage phenotype such as  
arginase-1 (ARG-1), TGF induced (TGFI) and fibronectin-1 (FN-1). In addition, 
alveolar trafficking of MPs in response to Pam3CSK4 elicited marked induction of 
genes encoding enzymes involved in PG and leukotriene (LT) metabolism such as  
COX-2, prostaglandin E synthase (PTGES) as well as LT C4 synthase (LTC4S) 
and LT B4 12-hydroxydehydrogenase (LTB4DH). Opposite down regulation was 
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observed for arachidonate 12-lipoxygenase (ALOX12) and hydroxyprostaglandin 
dehydrogenase 15 (HPDG) transcripts. 
Finally, a large number of genes encoding surface receptors were differentially 
regulated in MPs recruited to the lung by alveolar exposure to Pam3CSK4. Thus we 
observed elevated transcript levels in alveolar MPs for PRR genes such as CD14, 
TLR2, CLEC4N and scavenger receptor (SR)-A and reduced levels for IL-10 
receptor and M-CSFR (known as CD115). Moreover, alveolar trafficking of 
mononuclear phagocytes was found to be associated with marked up-regulation of 
some of G-protein coupled receptors (GPCRs) such as GPR31C, GPR137B, 
GPR84 and GPR178.  
To determine which gene ontology (GO) categories were statistically  
over-represented among the genes found to be the differentially regulated in 
alveolar recruited vs. circulating MPs we used the web-based tool GENECODIS 
(91). When grouped according to the biological processes, GO analysis highlighted 
a significant over-representation of molecules associated with 
inflammatory/immune responses including genes involved in chemotaxis (e.g. 
C3AR1 and FPR-1), apoptosis (e.g. FAS and CD40) and phagocytosis (such as 
CD23 and CD64). In addition, genes related to protein and ATP biosynthesis and 
lipid storage were significantly over-represented (Table 4.4).  
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Table 4.4 Gene ontology (GO) biological processes classification of differentially regulated 
genes 
GO analysis was performed online using GENECODIS web-based tool. 
GO annotations Biological process P
GO:0006412,GO:0006418 protein biosynthesis, tRNA aminoacylation for protein translation 0.006
GO:0006915,GO:0006955 apoptosis, immune response 0.008
GO:0006911,GO:0007166,
GO:0050766
phagocytosis, engulfment, cell surface receptor linked signal transduction, 
positive regulation of phagocytosis 0.009
GO:0006935,GO:0007165,
GO:0007600 chemotaxis, signal transduction, sensory perception 0.012
GO:0006754,GO:0006810,
GO:0006811,GO:0015986,
GO:0015992
ATP biosynthesis, transport, ion transport, ATP synthesis coupled proton 
transport, proton transport 0.012
GO:0007166,GO:0042535
cell surface receptor linked signal transduction, positive regulation of tumor 
necrosis factor-alpha biosynthesis 0.02
GO:0019915 lipid storage 0.02
GO:0006754,GO:0006810,
GO:0006811,GO:0015992 ATP biosynthesis, transport, ion transport, proton transport 0.02
GO:0007166,GO:0050776 cell surface receptor linked signal transduction, regulation of immune 
response 0.02
GO:0000074,GO:0006955 regulation of cell cycle, immune response 0.02
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4.3.3 Real time PCR validation of microarray results 
To verify the microarray findings, we performed quantitative real-time PCR for 
selected genes without SMART pre-amplification step. Genes chosen for validation 
were preferentially related to inflammatory processes. Heterozygous CX3CR1+/GFP 
mice received i.t. application of Pam3CSK4 (50 μg/mouse) for 24 h. The results 
obtained by real-time PCR largely matched with the microarray based gene 
expression profiles (Figure 4.14). However, real-time PCR data did not provide any 
evidence for differential expression of PTGES, FN1 and ANXA-1. The mRNA 
levels measured by real-time PCR tended to be higher than gene expression 
levels determined by arrays, what is expected and due to the pre-amplification and 
the lower dynamic range of the microarray signals. The mRNA levels of IL-1RN 
and IL-10 were below the detection limit in PB MPs but could be consistently 
detected in alveolar MPs in four independent experiments, indicating the up-
regulation of these genes upon recruitment. Vice versa, ALOX12 mRNA levels 
found to be below the detection limit in alveolar MPs in four separate experiments 
were consistently detectable in circulating MPs indicating ALOX12 down-regulation 
upon recruitment.  
In our model of TLR2 ligand Pam3CSK4-initiated lung inflammation we 
observed a significant decrease of recruited neutrophils together with an increase 
of MP infiltrates at 48 h compared to 24 h post challenge (Figure 4.11 and 4.12). 
Since this shift is considered to be a key histological hallmark of inflammatory 
infiltrate resolution we decided to determine whether MPs recruited until 48 h post 
challenge differentially regulate inflammatory mediators compared to 
corresponding cells recruited until 24 h. Therefore we monitored changes in the 
gene expression profiles of molecules related to inflammation of recruited MPs 
recovered from BALF after 48 h compared to 24 h after i.t. application of 
Pam3CSK4. Interestingly, we noticed that mRNA levels of pro-inflammatory 
molecules such as TNF-, IL-6, CCL2 or IL-12A were significantly lower in 
recruited MPs isolated from BALF at 48 h compared to 24 h, whereas the data did 
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not provide evidence for differential expression of gene with key anti-inflammatory 
and resolution function such as IRAK-M, IL-10, IL1-RN, BAX and ANXA-1 (Figure 
4.15). 
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Figure 4.14 Real-time quantitative PCR validation of microarray data 
CX3CR1 +/GFP mice were either left untreated or i.t. administrated with Pam3CSK4 (50 μg/mouse) for 
24 h. After cell sorting, RNA was isolated and the relative mRNA level of each gene was 
determined using real-time PCR as described in Materials and Methods. The coefficients values 
from microarray analysis (grey bars) were compared with CT values from real-time PCR (white 
bars). Data are given as mean ± SEM. Mean CT of MPs isolated from blood and alveolar 
compartment were compared using t-test. * indicates P at least < 0.05. 
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Figure 4.15 Time-dependent changes in the gene expression profile of alveolar recruited 
MPs  
CX3CR1 +/GFP mice were either left untreated or i.t. administrated with Pam3CSK4 (50 μg/mouse) for 
24 h or 48 h. After cell sorting, RNA was isolated and the relative mRNA level of each gene was 
determined using real-time PCR as described in Materials and Methods. Relative gene expression 
was calculated using the CT method. The results are given as mean ± SEM from three 
independent experiments. Mean CT of samples collected at different time points post-treatment 
were compared using t-test. * indicates P at least < 0.05. 
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5 DISCUSSION 
The aim of the current study was to analyse the molecular programs activated by 
bacterial ligands in alveolar resident as well as alveolar recruited MPs. We have 
found that key antiviral defence molecule named PKR is critically involved in an 
inflammatory response of AMs to gram-positive as well as gram-negative bacteria 
cell wall components in vitro. We have also analyzed, by microarray technology, 
the whole genome response of MPs recruited from circulation to the alveolar space 
following pulmonary challenge with the TLR2 ligand Pam3CSK4. We found that 
lung recruited MPs displayed simultaneous induction of both pro- and anti-
inflammatory genes. In addition, we observed a dynamic change of the genetic 
program in MPs obtained from BALF at different time points post alveolar TLR2 
ligand deposition. 
5.1 Requirement for PKR in TLR2/4-medaited signalling in 
murine AMs 
To identify novel molecular pathways activated in resident AMs by the E. coli LPS 
(TLR4 agonist) and synthetic lipoprotein Pam3CSK4 (TLR2 agonist) we performed 
a gene expression screen of selected TLR associated molecules. We found that 
both TLR2 and TLR4 ligand induced a similar expression pattern of TLR molecules 
in vitro and in a murine model of lung inflammation. The screen confirmed that TLR 
ligands induced activation of previously reported genes such as TNF-, IL-6, 
SOCS proteins and IRAK-M. Interestingly, our gene expression study identified an 
antiviral defence gene named PKR that was significantly up-regulated by bacterial 
ligands in vitro and in murine model of lung inflammation. It has been previously 
reported that LPS induced PKR mRNA in peritoneal and  
ANA-1 macrophages, but the regulation of PKR gene expression in AMs was 
unknown (92). Furthermore, our experiments demonstrated for the first time that 
also TLR2 ligand (synthetic lipoprotein Pam3CSK4) is a potent inducer of PKR 
mRNA and protein in vitro.  
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In contrast to the in vitro observations, we noticed that agonists for distinct TLRs 
differentially regulated PKR transcription in vivo. The expression of PKR in AMs 
was significantly increased after alveolar deposition of LPS at 6 h post challenge 
and decreased at later time points (24 h post challenge). In contrast, alveolar 
administration of Pam3CSK4 did not affect PKR mRNA levels at any of the 
analysed time points. Altogether, our findings suggest that PKR could be involved 
in TLR downstream signalling in AM during pulmonary bacterial infections.  
PKR is a serine/threonine protein kinase ubiquitously expressed in the cytoplasm 
that can be induced by IFN and dsRNA. This enzyme was initially characterized as 
translational inhibitor in IFN-induced antiviral response (93). It contains two 
functionally distinct domains: an N-terminal ds-RNA binding domain (DBD) and a 
C-terminal kinase domain (KD). Binding of dsRNA induces PKR dimerization, 
trans-autophosphorylation and subsequent phosphorylation of substrate targets. 
The most intensively characterised cellular substrate of PKR kinase activity is the 
alpha subunit of the eukaryotic translational initiation factor 2 (eIF-2), a 
heterotrimeric protein (composed of: ,  and  subunits), that binds guanosine 
triphosphate (GTP) and the initiator tRNAimet to form a ternary complex. This 
ternary complex eIF2–GTP–Met-tRNAimet binds to the 40S ribosomal subunit to 
form a 43S preinitiation structure, which binds mRNA and 60S ribosomal subunit 
with concomitant hydrolysis of GTP. To promote another round of translation 
initiation, guanosine diphosphate (GDP) associated with free eIF-2 must be 
exchanged for GTP by the activity of eIF-2B complex. Phosphorylation of eIF-2 
on Ser51 leads to the inhibition of protein synthesis by preventing the recycling of  
eIF-2. The phosphorylated form of eIF-2 cannot form a ternary complex with the 
initiator tRNAmet and the 40S ribosomal subunit. As a consequence, 
phosphorylation of eIF-2 by activated PKR leads to the shutdown of protein 
synthesis, resulting in a block of virus replication and selective apoptosis of the 
infected cells. Translation is highly sensitive to inhibition by activated PKR and 
phosphorylation of only 10-20% of eIF-2 suffices to block translation. In addition 
to its role in antiviral defence, PKR is involved in many aspects of cellular function 
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including, protein synthesis, cell growth, differentiation, tumor suppression and 
apoptosis.  
Recently, a growing number of evidence implicated PKR in several signal 
transduction pathways activated by a wide range of pro-inflammatory factors 
including LPS, dsRNA, TNF- and IL-1 (93). Cytokines and bacterial products 
activate indirectly PKR via upstream activators that could be kinases or other 
protein activators (Figure 5.1) (93). PKR has been shown to mediate activation of 
important transcription factors such as NF-kB (by poly I:C) (94), ATF-2 (by poly I:C 
and TNF-), STAT1 (by IFN- and LPS) (95) or IRF-1 (by dsRNA) (96). It has been 
also suggested that PKR is involved in TLR signalling in various cell types such as 
glial cells, fibroblasts or mast cells. However, there are no reports addressing PKR 
function in lung innate immunity in response to bacterial PAMPs.  
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Figure 5.1 Functions of PKR in signal transduction and translation  
dsRNA produced as a result of virus infection, cytokines and bacteria activate PKR, inducing 
dimerization and autophosporylation and allowing the PKR kinase to phosphorylate substrate 
targets. For instance, by phosphorylation of  subunit of EIF2, activated PKR inhibits translation. In 
addition, proteins such as PACT/RAX have been reported to directly associate with PKR, similarly 
stimulating autophosphorylation. PKR has additionally been reported to be involved in regulating a 
number of signalling pathways involving TNF-, NF-kB, although the mechanisms of action remain 
to be determined. Adapted and modified from Barber 2005 (97). 
 
5.1.1 TLR2 and TLR4 agonist induced phosphorylation of PKR 
Autophosphorylation is the first step in converting PKR to its active form (98). Our 
experiments have demonstrated for the first time that in AMs not only LPS induced 
TLR4 signalling but also Pam3CSK4 induced TLR2 signalling stimulated PKR 
phosphorylation within minutes. In addition, using TLR deficient and mutated mice 
we could show that activation of PKR by LPS and Pam3CSK4 was strictly 
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dependent on the cellular expression of the respective PRR molecules. These data 
indicate that PKR can act as an early step in the TLR2/4 induced inflammatory 
response. However, the mechanism of PKR activation by TLR ligands remains an 
important issue to be explored. The properties of dsRNA as a negatively charged 
polysaccharide resemble LPS, but it is rather unlikely that LPS and Pam3CSK4 can 
directly bind to intracellular located PKR. Recently, Horng and colleges 
demonstrated that PKR is a downstream target of the TIRAP/Mal signalling 
pathway that is essential for TLR2 and TLR4 (99). Besides TIRAP, PKR has been 
shown to physically interact with other proteins such as MKK6 or PACT (100, 101). 
Thus, activation of PKR by TLR ligands is likely to require complex but rapid 
signalling pathways involving protein-protein interactions.  
To delineate the role of PKR in TLR2/4-mediated activation of AMs, we applied 
nucleoside analogue 2-AP. Previously, 2-AP has been shown to posses a relative 
specificity for the inhibition of PKR phosphorylation by competing with ATP (92). In 
earlier experiments, 2-AP selectively blocked the expression of various genes in 
response to dsRNA, IFNs and virus infection (102, 103). In our in vitro assays, we 
observed a strong inhibition of PKR phosphorylation by 2-AP, most probably by 
competitive inhibition of ATP at the PKR-ATP binding site. However, 2-AP also 
blocked PKR induction by TLR ligands, thereby suggesting that inhibitor may act 
on the kinase activity and gene expression of PKR. Our results are in contradiction 
to previous study demonstrating that 2-AP affects only phosphorylation, but not 
gene expression of PKR (54, 92). The reasons for such differences in the 2-AP 
effect on PKR gene expression may be a result of (a) cell type (ANA-1 
macrophages vs. primary AMs); (b) different concentrations of LPS and 2-AP used 
in the studies; and finally (c) the method and time point for evaluation of PKR 
gene-expression. It is also possible that 2-AP blocked the expression of genes 
directly involved in the regulation of PKR transcription but on the other hand PKR 
may regulate the transcription of it is own mRNA. Nevertheless, in our 
experimental system, we used 2-AP to specifically blocked PKR phosphorylation.  
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5.1.2 PKR-dependent secretion of TNF- and IL-6 cytokines  
Pro-inflammatory cytokines are known to be important in the host response to 
pulmonary bacterial infections. They contribute to the recognition of pathogens, 
recruitment of immune cells from bloodstream to inflamed tissues and the removal 
of the invading pathogens (54, 104). TNF- is a typical pro-inflammatory cytokine 
primarily produced by MPs. Production of TNF- is increased in patients with 
pneumonia and in animal models of pulmonary infection caused by  
S. pneumoniae, Klebsiella pneumoniae or Pseudomonas aeruginosa (54). One 
consequence of elevated levels of TNF- is increased IL-6 production. IL-6 
induces production of acute phase response proteins, reduces albumin and 
transferrin levels and directs differentiation of B cells to immunoglobulin-producing 
plasma cells (75).  
AMs play a primary role in inflammation, principally through elaboration of variety 
of cytokines including TNF- and IL-6. To delineate the role of PKR in AM cytokine 
secretion, 2-AP and PKR KO mice were used. Our data clearly demonstrated that 
PKR is closely involved in inflammatory cytokine secretion. In addition, using PKR-
KO AMs we provided data that confirm the specificity of 2-AP as a valuable PKR 
inhibitor in our system. The profound decrease of PAMP-induced TNF- and IL-6 
production after PKR inhibition suggests that PKR activity may also determine the 
extent of alveolar inflammation in vivo. However, inhibition of PKR did not 
completely abolish the cytokine production. It will be interesting to evaluate 
whether remaining cytokines are still potent inducers of inflammatory response. 
Our results support the pro-inflammatory properties and immune defence activities 
of PKR, proposed in various cell types. Goh and co-workers demonstrated that 
PKR-deficient mouse embryonic fibroblasts (MEFs) were unable to cytokine 
production in response to bacterial LPS. Moreover, IL-6 and IL-12 p40 serum 
levels after intra peritoneal (i.p.) LPS challenge were diminished in PKR-KO mice, 
suggesting requirement of PKR in TLR4-mediated inflammatory responses (88). 
Therefore, the requirement for functional PKR in animal model of lung 
inflammation/infection needs to be evaluated. PKR was also found to play a crucial 
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role in the regulation of inflammatory cytokine expression in human blood 
monocytes stimulated with bacillus Calmette-Guerin (BCG) (89).  
5.1.3 Requirement of PKR for LPS induced activation of NF-B 
Binding of bacterial PAMPs to their respective TLRs leads to increased production 
of inflammatory cytokines and chemokines. Expression of pro-inflammatory genes 
is regulated by transcriptional mechanisms. NF-B represents one of the major 
transcription factors linked to the production of variety of inflammatory mediators 
including TNF-, IL-6, IL-12 and CCL2 (45). The main regulatory mechanism of 
NF-B activation is mediated by interaction with the IB proteins that retain NF-B 
proteins in the cytoplasm in an inactive state. On exposure of the cell to activation 
signals such as LPS, IB proteins are phosphorylated by IB kinases (IKKs). The 
phospho-IB proteins become targets for ubiquitination and degradation, whereas 
NF-B proteins are translocated to the nucleus to activate the transcription of 
cognate genes. There have been a number of proteins identified as possible IKKs 
(42, 44, 45).  
The NF-B link to PKR was suggested by a series of experiments showing that 
dsRNA could activate NF-B in various cell lines, however the mechanism still 
remained controversial (105). PKR has been proposed to be a component of the 
IKK complex and directly phosphorylates IB proteins (106). For example, 
induction of E-selectin, an important for leukocyte rolling adhesion molecule, by 
TNF- and poly I:C is impaired in PKR-KO endothelial cells due to the defective 
activation of NF-B (107). Similarly Gon and colleges observed that pre-treatment 
of cells with 2-AP attenuated LPS-induced NF-B activation in RBL-2H3 mast cells 
(90). Other groups, however, reported that activation of NF-B by inflammatory 
stimuli did not require PKR kinase activity (108). Der and co-workers showed that 
PKR gene deletion had no effect on TNF- or LPS-induced NF-B activation (96). 
Our work supports requirement for PKR phosphorylation in NF-B activation in 
response to LPS. Using both pharmacological inhibition and gene KO approaches 
we have demonstrated that LPS-induced activation and translocation of p65 
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depends on PKR phosphorylation. However, we could observe that NF-B remains 
still active in PKR-KO AMs, suggesting that PKR-independent activation of NF-B 
exists. Our results differ with those of Hsu and colleges, who found that PKR-KO 
BM derived macrophages (BMDMs) exhibited normal IKK activation and normal 
induction of numerous NF-B target genes in response to LPS (109). These 
different observations may be due to distinct mechanisms of NF-B activation in 
different macrophages subsets in mice.  
In contrast to LPS, TLR2-mediated activation of NF-B was found to be largely 
PKR phosphorylation-independent. This finding suggests that the molecular steps 
regulating NF-B activity differ in TLR2 and TLR4 mediated signalling pathways of 
AMs.  
5.1.4 PKR dependent regulation of the JNK signalling pathway  
The MAP kinases are a family of evolutionary conserved enzymes that connect 
cell surface receptors to regulatory targets and coordinate activation of gene 
transcription, protein synthesis, cell cycle machinery, cell death, and differentiation 
(23, 24). They represent the second major signalling pathway activated by TLRs in 
AMs involved in cytokine production (29). The connection between MAPK and 
PKR has been recognized just recently, through only a few studies. Goh and co-
workers demonstrated for the first time that PKR-deficient MEFs were unable to 
activate p38 and JNK MAP kinases in response to bacterial LPS or poly I:C (88). 
Moreover, authors observed that activation of the specific MAPK kinases, MKK3 
and MKK6 activating p38 MAPK and MKK4 activating JNK MAPK, were 
correspondingly reduced in PKR-deficient MEFs after stimulation with LPS or poly 
I:C. Interestingly, JNK activation was no longer dependent on PKR activity in 
immortalized fibroblast cell lines generated from the MEFs (88). Similarly, Cheung 
and colleagues revealed that the early signal transduction events of mycobacterial 
activation of human monocytes requires PKR dependent ERK phosphorylation 
(89). In our study, we observed phosphorylation of three major MAP kinases, p38, 
JNK and ERK1/2 in response to Pam3CSK4 and LPS in AMs. Inhibition of PKR 
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phosphorylation by 2-AP and gene deletion in PKR-KO AMs however abolished 
PAMP-induced JNK but not ERK1/2 MAPK and p38 MAPK activation. Our results 
are in line with those of Goh and colleagues, who found that PKR was required for 
efficient activation of JNK by LPS in primary low-passage MEFs (88). However, 
our results differ from those of Hsu and colleagues, who found that BMDMs 
derived from PKR-KO exhibited normal p38, JNK and ERK MAP kinases activation 
in response to LPS (109).  
JNK have been reported to be an important mediator of the production of 
inflammatory cytokines induced by LPS. A critical role for JNK appears to be the 
regulation of the AP-1 transcription factor through phosphorylation of  
the N-terminal part of c-Jun, a central component of AP-1 (29, 31). 
Correspondingly, we observed reduced phosphorylation of c-Jun/AP-1 when PKR 
was inhibited. In addition, phosphorylation of MKK4, a direct activator of JNK, was 
found to be dependent on PKR activity. Collectively, these data indicate that PKR 
specifically regulates the JNK signalling pathway (PKR-MKK4-JNK-c-Jun) in AMs 
activated by TLR2 and TLR4 agonists. Our results suggest that there are multiple 
pathways for JNK, p38 and ERK1/2 MAPK activation in AMs. Moreover our 
observations support the idea that PKR can be one of the MAPKKKs (93).  
In summary, our study shows that the secretion of TNF- and IL-6 by primary AMs 
in response to cell wall components of gram-positive as well as gram-negative 
bacteria in vitro is critically dependent on PKR phosphorylation. Activated PKR 
was found to act upstream of the Pam3CSK4 and LPS-activated JNK pathway. 
PKR also regulates TLR4- but not TLR2-induced activation of NF-B in AMs. 
These data identify PKR phosphorylation as important signalling step in the 
TLR2/4-mediated inflammatory response of AMs to bacterial PAMPs (Figure 5.2). 
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Figure 5.2 Model of PKR transducer function in TLR2/4-mediated signalling  
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5.2  Transcriptional profiling of MPs recruited to mouse 
lungs in response to alveolar challenge with the TLR2 
agonist Pam3CSK4 
5.2.1 Alveolar trafficking of PB MPs is associated with global 
changes in their gene expression profile 
MPs represent a central part of both the innate and adaptive immune response to 
pathogens. Under steady-state condition, half of the circulating MPs leave the 
bloodstream each day to enter peripheral tissues (59). Inflammatory stimuli such 
as invading pathogens or TLR ligands, however, elicit increased MP traffic to the 
sites of inflammation where MPs can modulate local host responses by e.g. 
secreting inflammatory mediators such as cytokines, chemokines and lipids (55). 
Compared to the TLR4 ligand LPS restricted to gram-negative bacteria, a limited 
number of studies have addressed the induction of lung inflammation and the 
concomitant MP recruitment in response to TLR2 ligands. Consequently, in vivo 
experimental data on migration and function of MPs recruited to the lungs in 
response to TLR2 agonists are rare. 
This study is the first report showing that selective TLR2 ligand stimulation within 
the alveolar compartment likewise promoted lung inflammation in mice and 
induced the migration of circulatory immune cells including MPs into the inflamed 
alveolar space. This model seems of considerable interest because most cases of 
community acquired pneumonia (CAP) are caused by gram-positive bacteria 
lacking LPS but expressing TLR2 ligands. Our study also represents the first 
global expression profiling of MPs recruited from the circulation to the alveolar 
compartment in response to the TLR2 agonist Pam3CSK4. By combination of 
FACS cell sorting, mRNA amplification methods and whole genome microarrays 
we were able to profile MP transcriptome from small amounts of BALF and blood 
of Pam3CSK4-treated mice. We found that expression of approximately 2500 
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genes was significantly changed in alveolar recruited MPs compared to circulating 
MPs. In particular, trafficking of MPs was associated with drastic up-regulation of a 
broad array of pro-inflammatory molecules including TNF-, IL-1/, IL-6, 
CXCL16, KC or CCL2 indicating that inflammatory elicited MPs bear the potential 
to promote lung inflammation by increasing alveolar levels of cytokines and 
chemotactic mediators for neutrophils, monocytes and lymphocytes. This 
observation supports previous reports in which MPs were identified as active 
contributors to the development of acute lung inflammation in patients with ALI and 
were shown to promote neutrophil recruitment in response to alveolar challenge 
with LPS in mice (70, 110). Interestingly our transcriptome analysis revealed that 
Pam3CSK4 challenge induced not only pro-inflammatory but also pronounced  
anti-inflammatory MP responses. Thus we noticed strong up-regulation of IL-1RN, 
IRAK-M, IL-10, ANXA-1, BAX, IL-18BP and FPR-1 genes in alveolar recruited 
MPs.  
IL-1RN acts as specific inhibitor of IL-1/ signalling by competitive binding to the 
IL-1 receptor. Previous reports already demonstrated that IL-1RN is mainly 
produced by monocytes/macrophages in response to TLR4 ligands such as LPS 
(75). Thus, the strong increase of alveolar MP IL-1RN transcripts observed after 
Pam3CSK4 administration suggests a potential role for IL-1RN in blocking the 
action of IL-1/ and in limiting of TLR2 driven lung inflammatory responses.  
IRAK-M represents another host strategy evolved to dampen inflammatory TLR 
signalling. IRAK-M negatively regulates MyD88 dependent TLR2/4/9 signalling by 
inhibiting the dissociation of IRAK1 and IRAK4 from the TLR complex (22). In vivo, 
IRAK-M-deficient mice exhibited increased inflammatory response during bacterial 
infections (111). Moreover, it has been demonstrated that lung macrophages from 
IRAK-M–deficient septic mice produced higher levels of pro-inflammatory 
cytokines such as IL-12 and TNF- when stimulated with LPS ex vivo (112). After 
Pam3CSK4 challenge augmented IRAK-M transcript levels were found in alveolar 
recruited MPs both at 24 and 48 h. These data suggest that activation of IRAK-M 
may represent a potential mechanism to limit TLR2-medaited pulmonary 
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inflammation. Our study revealed that Pam3CSK4 induced high up-regulation of  
IL-10 mRNA levels in alveolar MPs. IL-10 is an important immunomodulatory 
cytokine with known anti-inflammatory and immunosuppressive properties (75). It 
has been shown that LPS-induced secretion of IL-10 limits production of  
pro-inflammatory cytokines including TNF-, IL-1 and IL-12 thereby promoting the 
termination of inflammation (113). Consequently increase of anti-inflammatory and 
pro-resolving transcripts observed after Pam3CSK4 administration suggests a 
potential role for alveolar recruited MPs in limiting TLR2 driven lung inflammatory 
responses.   
Lipids such as arachidonic acid derivatives are potent inflammatory mediators 
(114). Our gene array data revealed that inflammatory trafficking of MPs was 
associated with profound regulation of genes involved in PG and LT metabolism 
such as COX-2 and PTGES. COX-2 catalyzes PG synthesis including PGE2 
commonly considered as central pro-inflammatory lipid mediator involved in the 
pathogenesis of several inflammatory diseases such as periodontitis and 
rheumatoid arthritis (115, 116). In lungs, however, it has been reported to display 
anti-inflammatory and pro-resolution activity as well (117). For example PGE2 has 
been shown to down-regulate the production of pro-inflammatory cytokines such 
as IL-12 or CCL2 thus inhibiting inflammatory cell recruitment (118). In addition, 
the expression of the genes encoding the enzymes LTB4DH involved in 
deactivation of the PMN chemoattractant LTB4 and HPGD promoting the 
deactivation of PGs and lipoxins were found to be up-regulated in MPs recruited to 
the alveolar air space. Thus by alveolar recruitment, MPs may acquire the potential 
to actively contribute to lowering the local levels of lung lipid inflammatory 
mediators. 
In vivo studies indicated the potential of circulating MPs to differentiate into lung 
macrophages under both inflammatory and non-inflammatory conditions (56). 
Recently macrophages have been assigned to two groups: classically activated 
(pro-inflammatory activities) and alternatively activated macrophages (anti-
inflammatory activities) (119). In our study we found that i.t. administration of 
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Pam3CSK4 elevated mRNA levels of genes such as SPP-1, ARG-1, TGFI, FN-1 
and IL-10 that are preferentially associated with an alternatively activated 
macrophages phenotype. Alternatively activated macrophages are known to play a 
major role in tissue repair during the healing phase by secretion of extracellular 
matrix (ECM) components and release of anti-inflammatory mediators (119). 
Based on these results freshly recruited MPs may represent important factors for 
the resolution of pulmonary inflammation.  
The present work also revealed differential expression of GPCRs with unknown 
function such as GPR31C, GPR137B.and GPR178 in lung recruited compared to 
circulating MPs. Since different stages of mononuclear phagocyte differentiation 
are characterized by different repertoires of GPCR, these differentially regulated 
receptors may reflect MP changes during migration to the lungs. However, the 
potential role of these molecules during lung inflammatory processes remains to 
be further elucidated in detailed functional studies.  
5.2.2 Attenuation of pro-inflammatory gene expression levels in 
alveolar MPs during late inflammatory response phases 
As unbalanced production of pro-inflammatory mediators may lead to inflammatory 
damage of the highly sensitive respiratory structures, the activation of host defence 
responses in the lung must be tightly regulated and later terminated (120). 
Numerous control strategies have been evolved including inhibition of  
pro-inflammatory mediators and secretion of anti-inflammatory and pro-resolving 
mediators. In our model of TLR2 ligand Pam3CSK4-initiated lung inflammation, 
intense inflammatory injury peaks at 24 h post challenge and then slowly recedes. 
At the cellular level, these events are characterized by increased trafficking of MPs 
and reduced neutrophil accumulation within the lung. This observation is 
consistent with the current concept of cellular inflammation resolution. Elucidation 
of molecular programs activated in MPs during this late phase may provide 
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important insights into how MPs contribute to the termination of TLR2 mediated 
lung inflammatory diseases.  
In this respect, we monitored temporal changes in the gene expression of pro- and 
anti-inflammatory mediators of alveolar recruited MPs at 24 h and 48 h post 
Pam3CSK4 treatment. We found that mRNA levels of pro-inflammatory molecules 
such as TNF-, IL-6, CCL2 and IL-12A were significantly lower in BALF MPs at 48 
h compared to BALF MPs at 24 h, whereas gene expression of molecules with key 
anti-inflammatory and pro-resolution function such as IRAK-M, IL-10, IL1-RN, BAX 
and ANXA-1 persisted at the same level at 48 h and 24 h. Thus MPs recruited 
during later phase of inflammation, activate regulatory mechanisms to switch off 
the pro-inflammatory phenotype overrepresented during maximal inflammation. 
Moreover, by persistent high induction of IL-10 and IL1-RN genes MPs may 
actively contribute to the termination of inflammation.  
Recruitment of MPs from the circulation to the alveolar space is a multistep 
process involving multiple cellular interactions. In addition, after trafficking to the 
airspace MPs become exposed the specialized alveolar microenvironment 
stimulated by PAMP induced inflammation with the potential to further modulate 
the phenotype of the recruited cell population. Our global gene profiling approach 
does not allow to assign the observed changes in the genetic program of lung 
recruited MPs to any of these migratory steps. We also cannot discriminate 
whether the changes in gene activation found in alveolar recruited MPs at 48 vs. 
24 h are due to phenotype changes occurring in MPs within the alveolar 
compartment or reflect the recruitment of functionally different MP during later 
stages that have acquired altered functional programs either within the vascular 
compartment or during the trafficking process. The fact, however, that the gene 
expression profiles of circulating MPs obtained at 48 vs. 24 h also display a shifted 
profile suggests that indeed the extravasation of functionally modified MPs may 
contribute to the altered gene expression profile of BALF MPs at later time points 
after inflammatory challenge. 
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In conclusion, our data demonstrates the feasibility to evaluate cell specific 
transcriptome profiles in highly purified flow sorted MPs from both PB and BALF in 
a mouse model of TLR2 ligand induced lung inflammation. We identified more than 
3500 genes differentially expressed, mostly up-regulated in alveolar recruited 
compared to PB MPs demonstrating that inflammatory MP trafficking into lung 
tissue was associated with large scale genetic program activation. Notably, the MP 
gene clusters undergoing activation in response to i.t. Pam3CSK4 application 
encoded both pro- and anti-inflammatory activities, however with a profound profile 
change over time. MPs recruited within 24 h post challenge showed simultaneous 
induction of both pro- and anti-inflammatory genes, whereas in MPs isolated from 
BALF after 48 h post challenge mainly genes encoding anti-inflammatory 
mediators were found to persist in an up-regulated. Collectively, our results provide 
important new insights into how MPs contribute to the promotion and 
termination/resolution of TLR2 mediated inflammation. 
5.3 Future perspectives 
Cell specific profiles of the molecular programs induced by gram-positive as well 
as gram-negative bacteria ligands in pulmonary MPs provide important insights 
into the host defence molecular network in infectious lung diseases such as 
pneumonia and ARDS. In the present study we aimed to analyse the molecular 
programs activated by TLR2/4 ligands in alveolar resident as well as alveolar 
recruited MPs to further delineate their role in pulmonary defence. This knowledge 
may help to identify new molecular targets for selective therapeutic intervention in 
pneumonia.  
We discovered that key antiviral defence molecule PKR was activated and critically 
involved in inflammatory response induced by bacterial TLR agonists in AMs in
vitro. Our data clearly demonstrate that treatment with specific pharmacological 
inhibitor 2-AP and PKR gene deletion reduced acute inflammatory cytokine 
response. Therefore modulation of PKR activity may have a therapeutic potential 
in treatment of patients during pulmonary bacterial infections.  
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Since S. pneumoniae and K. pneumoniae are frequently isolated causative 
pathogens of pneumonia it is reasonable to determine the role of PKR in host 
defence in gram-positive and gram-negative pneumonia in mice. Nevertheless, 
studies with human samples are required to clarify the role of PKR during bacterial 
lung infections in patients. Since several cancer drugs have been shown to 
modulate PKR activity; their potential in the treatment bacterial lung infections 
should be evaluated. 
In addition to activation of lung resident cells, alveolar recognition of inhaled 
pathogens promotes increased recruitment of circulating MPs to inflamed tissue. 
Therefore we examined the global gene expression profiles of MPs recruited from 
peripheral blood to the alveolar space following alveolar deposition of the TLR2 
ligand Pam3CSK4. We found that alveolar trafficking of MPs was associated with 
profound changes of their gene expression profiles post recruitment. Importantly, 
whereas the induced mRNA levels of selected pro-inflammatory mediators were 
found to decrease during later inflammation phases, the increased transcript levels 
of central anti-inflammatory mediators persisted. To further study the role of MPs in 
TLR2-driven inflammatory response it would be interesting to evaluate whether the 
transcriptome level changes are also reflected at the proteome and metabolome 
level. These studies should be also complemented by whole genome expression 
profiling of MPs recruited to the lungs in response to infection with TLR2 ligands 
bearing gram positive bacteria such as S. pneumoniae. It is known that MPs are 
not a homogenous population. In our study using CX3CR1+/GFP mice we were not 
able to specifically monitor MP subset specific changes in gene expression. In 
addition, we could not discriminate whether the changes in gene expression found 
in alveolar recruited MPs at 48 h vs. 24 h are due to phenotype changes occurring 
during migratory processes. Therefore it will be of interest to isolate distinct 
alveolar and vascular populations of recruited MPs and perform gene expression 
analysis. In addition using specific KO mouse models or gene silencing strategies 
would be helpful to further define the role of alveolar recruited MPs and their 
relative contribution to the lung inflammatory response.  
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Table 6.1 List of primers used for quantitative real-time PCR  
 
Target Genebank  Sequence (5’3’) 
accesion forward revere gene 
      
ANXA1 NM_010730 CGTGAAGTGTGCCACCAGC CGAACGGGAGACCATAATCCT 
BAX NM_007527 TCAAGGCCCTGTGCACTAAAG ATCCAGACAAGCAGCCGCT 
CCL2 NM_011333 AGCATCCACGTGTTGGCTC CCAGCCTACTCATTGGGATCAT 
CD36 NM_007643 ATGCCAGTCGGAGACATGC TGGTGCCTGTTTTAACCCAGT 
COX-2 NM_011198 AGCCTTCTCCAACCTCTCCT CAGGGATGAACTCTCTCCGT 
FPR-1 NM_013521 GGAGATCAGCTGTAGATCTGT GAGGTTCACTGCAGACTTGTT 
HPGD NM_008278 CATCGGATTCACACGCTCAG CAATGGATTCAAGGATGG 
IL-10 NM_010548 CAGAGAAGCATGGCCCAGA TGCTCCACTGCCTTGCTCTTA 
IL-12A NM_008351 AGACCACAGATGACATGGTGA GTCCCGTGTGATGTCTTCAT 
IL-1RN NM_031167 TCCTGTTTAGCTCACCCATGG CCAGCAATGAGCTGGTTGTTT 
IL-6 NM_031168 ACAAAGCCAGAGTCCTTCAGAGAG GCTTATCTGTTAGGAGAGCATTGGA 
IRAK-M NM_028679 TGGACATTCGAAACCAAGCATA GGGTGACGGAACAGGAGTAGAA 
LCN2 NM_008491 CAGCTTTACGATGTACAGCACCA TCCAGTAGCGACAGCCCTG 
LTB4DH NM_025968 CAACCGTACTGGACCATG GCCACCGATTCACGATGAA 
LTC4S NM_008521 GGCAACATGAAGGACGAA GAAAGCCCTTCGTGCAGAGA 
PBGD NM_013551 GGTACAAGGCTTTCAGCATCGC ATGTCCGGTAACGGCGGC 
PKR NM_011163 AATCCCGAACAAGGAGAACAGG AGCTAGAATAAGGCCCAAAGCA 
PTGES NM_022415 ACCACCTGCAGGAGATGTA GGTCAGCAAGGTTAGGCTTC 
SIGIRR NM_023059 GTTAAGTGTCGGCTGAACATGC GTCGCTATAGGACACGTAGGCA 
SOCS-1 NM_009896 GGA GCA TGC GCG ACA GC CCT ACT CGA GGG GCC AGC T  
SOCS-3 NM_007707 GCC GGA GAT TTC GCT TCG GAG CCA GCG TGG ATC TGC 
SPP1 NM_009263 CTCGGAGGAAACCAGCCA GGATCTGGGTGCAGGCTGTA 
ST2 NM_010743 GCCACCAGATCATTCACAGTTG TGAACAGGCAATACTTGCTGGT 
TGFI NM_009369 ACCAATGAAGCGTTCCAAGC TGCCTCCGCTAACCAGGAT 
TLR2 NM_011905 CACCGGTCAGAAAACAACTTACC CAGAACAGCGTTTGCTGAAGAG 
TLR4 NM_021297 GAGCTTCAACCCCTTGAAGATCT GCCATGCCATGCCTTGTCT 
TNF- NM_013693 CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 
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Figure 6.1 ELISA for TLR2/4 ligands 
AMs isolated from TLR2-KO and TLR4 mutated (CC3TLR/J) mice were incubated with medium 
alone or treated with LPS (200 ng/ml) or Pam3CSK4 (2 	g/ml) for 6 h. Collected supernatants were 
assayed for TNF- concentrations by ELISA as described in Materials and Methods. Data are 
represented as mean ± SD of at least three different experiments. 
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Figure 6.2 TransAM assay control 
Activation of p65 subunit of NF-B was monitored using nuclear extracts of Jurkat cells (5 μg) as 
described in Materials and Methods. Briefly, unlabeled wild-type and mutated oligonucleotides were 
used to perform competition experiments against the provided biotinylated immobilized 
oligonucleotide. The wild-type consensus oligonucleotide will prevent NF-B binding to the probe 
immobilized on the plate. Conversely, the mutated consensus oligonucleotide should have no effect 
on NF-B binding. Results are presented as mean ± SD of at least three different experiments. 
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Figure 6.3 Secondary antibody control 
AMs from WT mice were incubated with medium alone. After washing, cells were incubated only 
with secondary Alexa fluor 488 labelled goat anti-rabbit Ig antibody (green) as described in 
Materials and Methods. Nuclei were counterstained with DAPI (blue). The cells were imaged by 
conventional microscopy. Images are representative of at least three independent experiments.  
 
Table 6.2 List of antibodies used for western blotting and immunofluorescence microscopy 
 
Primary
anti-phospho p38 rabbit  1:1000 Cell S ignalling
anti-p38 rabbit  1:1000 Cell S ignalling
anti-p65 NF-B rabbit  1:50 Santa Cruz
anti-cJun rabbit  1:1000 Santa Cruz
anti-phospho ERK1/2 rabbit  1:1000 Cell S ignalling
anti-ERK1/2 rabbit  1:1000 Cell S ignalling
anti-phospho J NK1/2 rabbit  1:1000 Cell S ignalling
anti-JNK1/2 rabbit  1:1000 Cell S ignalling
anti-phospho MKK4 rabbit  1:1000 Cell S ignalling
anti-phospho PKR rabbit  1:1000 Abcam
anti-PKR rabbit  1:1000 Santa Cruz
anti--actin rabbit  1:2000 Biolegend
Secondary
HRP -conjugated anti-rabbit IgG goat  1:3000 Pierce
Alexa Fluor 488 anti-rabbit IgG goat  1:3000 Invitrogen
Antibody Host Dilution Company
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